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Chapter 2 
 
ABSTRACT 
                  
 
Tumor angiogenesis is a process that requires migration, proliferation, and differentiation of 
endothelial cells. We hypothesized that decrease in pancreatic tumor growth due to inhibition of 
src activity is associated with the inability of src kinase to trigger a network of such signaling 
processes, which finally leads to endothelial cell death and dormancy of angiogenesis. 
The therapeutic efficacy of Src kinase inhibitor AZM475271 was tested in nude mice 
orthotopically xenografted with L3.6pl pancreatic carcinoma cells. No liver metastases and 
peritoneal carcinosis were detected and a significant effect on the average pancreatic tumor 
burden was observed following treatment with AZM475271, which in turn correlated with a 
decrease in cell proliferation and an increase in apoptotic endothelial cells. AZM475271 was 
shown to significantly inhibit migration of human umbilical vein endothelial cells in an in vitro 
Boyden Chamber cell migration assay. In a rat aortic ring assay we could demonstrate as well 
inhibition of endothelial cell migration and sprouting following therapy with Src kinase inhibitor 
at similar doses. Furthermore, we could show reduced proliferation of HUVECs determined with 
the TACS MTT Cell Viability Assay Kit. The blockade of Src kinase significantly reduced the 
level of VEGF in L3.6pl medium, the effect which was found also in the cell culture supernate 
from HUVECs. Inhibition of Src kinase by AZM475271 also showed prevention of survival 
signalling from VEGF and EGF receptors. Treatment with AZM475271 resulted in VEGF – 
dependent inhibition of tyrosine phosphorylation of FAK. HUVECs were also examined using 
propidium iodide staining for cell cycle analysis by FACS. Inhibition of src kinase promoted 
HUVEC apoptosis in a dose-dependent manner. 
Taken together, our results suggest that the Src kinase inhibitor AZM475271, in addition to its 
effects on tumor cells, suppresses tumor growth and metastasis in vitro and in vivo potentially 
also by anti-angiogenic mechanisms.  
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3.1 Pancreatic cancer 
 
3.1.1 Epidemiology and clinical characteristics  
 
Pancreatic cancer is one of the most fatal malignancies in humans and continues to be a major 
medical challenge in the western world. The incidence rate of about 10 per 100,000 equals the 
mortality rate, underscoring the devastating nature of this disease (Van Cutsem et al., 2004). The 
five-year survival rate for pancreatic cancer is very low, less than 3% (Jemal et al., 2002), the 
median overall survival is 3-6 months with a 12-month survival rate of 10% (Bramhall et al., 
1995). The very poor prognosis is due to late symptoms and the inability to detect this disease at 
early stages. Even with current diagnostic modalities, the inaccessible location of the pancreas 
often makes the diagnosis of pancreatic cancer a real challenge. Pancreatic cancer spreads early 
and most of the patients show liver or lymph node metastases at the time of diagnosis. More than 
80% of patients have disease-related symptoms, such as jaundice, pain, asthenia, weight loss, and 
poor performance status (Cascinu et al., 1999). Even though painless jaundice occurs in about 
50% of patients with respectable lesions of the pancreatic head, in general early symptoms are 
non-specific, and jaundice may also occur as a late symptom of large tumors of the body of the 
gland. Pain is the most frequent symptom and is present in 80% of patients with locally 
advanced tumors and metastatic disease (Van Cutsem et al., 2004). Nearly 90% of pancreatic 
neoplasms are adenocarcinomas, arising from the exocrine ductal system. They are most often 
multicentric and 75% are located in the head of the pancreas. The etiology of pancreatic cancer is 
not well understood but risk factors such as smoking, chronic pancreatitis and positive family 
history are implicated (Ahlgren, 1996; Hruban et al., 1998; Li et al., 2004). To date, surgical 
resection is the only potentially curative treatment, but the majority of patients are not surgical 
candidates due to advanced disease or significant co-morbidity (Brand 2001). For over 80% of 
pancreatic carcinoma patients, palliative treatment protocols represent the only reasonable 
therapeutic option (ASCO, 2006 Gastrointestinal Cancers Symposium).  
This information indicates that current interventions to prevent, diagnose, and cure the disease 
are far from satisfactory. Only the understanding of the molecular mechanisms of pancreatic 
carcinogenesis will provide novel clues for preventing, detecting and ultimately curing patients 
with this life-threatening disease. 
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3.1.2 Standard chemotherapy of pancreatic cancer 
 
Gemcitabine (2',2'-difluoro-2'-deoxycytidine) represents the current standard drug for cytotoxic 
therapy of advanced pancreatic cancer. Gemcitabine is a pyrimidine analog with a wide spectrum 
of antitumor activity (Abbruzzese, 1996). It is metabolized intracellulary by nucleoside kinases 
to the active species gemcitabine-diphosphate (dFdCDP) and gemcitabine-triphosphate 
(dFdCTP). Incorporation of dFdCTP into DNA is responsible for the cytotoxic effects of 
gemcitabine, via inhibition of DNA synthesis, DNA repair and ultimately via induction of 
apoptosis. Moreover, gemcitabine is a radio-sensitizing agent which acts specifically in the S and 
G1/S phase of the cell cycle.  
5-Fluorouracil (5-FU), a fluoropyrimidine analogue, is also one of the most commonly used 
anticancer drugs for the treatment of pancreatic cancer. Some studies reported that the 
cytotoxicity of fluoropyrimidines is mediated, in large part, by inhibition of the thymidylate 
synthase (Carreras et al; 1995). Thymidylate synthase (TS) is the critical target for 
fluoropyrimidine cytotoxic drugs. It provides the sole de novo source of thymidylate for DNA 
synthesis. TS catalyzes the methylation of dUMP (deoxyuridine-5'-monophosphate) to dTMP 
(deoxythymidine-5'-monophosphate), which forms a tight-binding covalent complex with TS 
(Danenberg, 1977).  
Based on the results from different randomized trials, first-line and second-line gemcitabine 
treatment in patients with advanced pancreatic cancer reveal significant advantages compared to 
5-FU treatment regarding disease stabilization, overall survival and clinical benefit response 
measured as a decrease in pain, functional impairment and weight loss (Burris et al., 1997; 
Carmichael et al., 1996; Casper et al., 1994; Rothenberg et al., 1996). Several studies have 
focused on gemcitabine plus cisplatin (Philip, 2002; Lund et al., 1996). However, a very recent 
meta-analysis of larger Phase II and Phase III trials did not show a significant advantage for 
gemcitabine-cisplatin combinations over gemcitabine monotherapy, regarding 6-month survival 
rate, clinical benefit and toxicity (Xie et al., 2006). Similary, combination of gemcitabine and 
irinotecan resulted in superior response rates but not in improvement of progression-free or 
overall survival (Rocha Lima et al., 2002, 2004; Stathopoulos et al., 2003). Other combinations 
with gemcitabine, such as the addition of docetaxel, pemetrexed and exatecan mesylate, have 
proved disappointing in larger trials (Jacobs, 2002; Kindler 2002; O’Reilly et al., 2004; Richards 
et al., 2004; Stathopoulos et al., 2001).  
Taken together, gemcitabine represents the current standard drug for therapy of advanced 
pancreatic cancer, and surgical patients might benefit from adjuvant gemcitabine therapy. New 
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conventional cytotoxic agents and other gemcitabine combinations might improve survival, but 
the improvement is likely to be small. Therefore, there is an urgent need for a better 
understanding of the mechanisms that contribute to pancreatic cancer growth and metastasis and 
for the design of more effective therapies for it.  
 
3.1.3 Molecular mechanisms of pancreatic carcinogenesis 
 
Over the past few years, our knowledge of the pathogenesis of pancreatic cancer has advanced 
significantly because of a rapid increase in our understanding of the molecular biology of it. Like 
many other malignant diseases, pancreatic cancer results from the accumulation of inherent and 
acquired genetic and epigenetic alterations. The multigenic nature of most pancreatic cancers is 
reflected by abnormalities of three broad classifications of genes: oncogenes, tumor suppressor 
genes and genomic maintenance genes (Sohn et al., 2000; Sakorafas et al., 2001). Accumulated 
alterations of such genes are believed to occur over a predictable time course. Based on the 
understanding of the histological and molecular genetic profiles of pancreatic cancer, 
investigators have developed a progression model that describes pancreatic ductal 
carcinogenesis: the pancreatic ductal epithelium progresses from normal epithelium to increasing 
grades of pancreatic intraepithelial neoplasia to invasive cancer (Hruban et al., 2000).  
The majority of pancreatic cancers occur sporadically and have been fairly well characterized at 
the genetic level. Pancreatic cancer pathogenesis is apparently involved in the activation of 
several oncogenes and/or inactivation of various tumor suppressor genes (Sohn et al., 2000; 
Kern, 2000). Since the identification of the first notable genetic alteration of the K-ras oncogene, 
there has been an explosion in our understanding of pancreatic cancer genetics (Sohn et al., 
2000; Kern, 2000). For examples, more than 85% of pancreatic cancers have an activating point 
mutation in the K-ras gene at a very early stage of development (Almoguera et al., 1988). Also, 
the tumor suppressor gene p16 is inactivated in about 95% of pancreatic cancers, and 
inactivation typically occurs late in pancreatic carcinogenesis. TP53, a well-characterized tumor 
suppressor gene located on chromosome 17p, is the second most frequently inactivated gene. 
Furthermore, DPC4 or SMAD4 is inactivated in 55% of pancreatic adenocarcinomas. Both TP53 
and DPC4 inactivation are late events in pancreatic tumorigenesis. Other less common genetic 
alterations continue to be described in pancreatic cancer. In a comprehensive mutational analysis 
of 42 pancreatic cancers, Rozenblum et al. (1997) found that all of the tumors harboured 
mutations of the K-ras oncogene. The individual mutational frequency of the tumor suppressor 
genes p16, TP53, MADH4 and BRCA2 was 82, 76, 53 and 10%, respectively. Presumably, these 
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alterations promote cellular proliferation, suppress apoptotic pathways, and facilitate tumor 
angiogenesis, invasion and metastasis. 
However, the molecular mechanisms that link these genetic changes with the aggressive nature 
of pancreatic cancer remain poorly understood. These genetic alterations are generally perceived 
to eventually lead to various abnormalities in the expression and functions of a variety of growth 
factors and their receptors and to affect their downstream signal transduction pathways involved 
in the control of cell proliferation and differentiation (Li et al., 2004; Sakorafas et al., 2001; 
Kern, 2000; Korc, 2003). For example, pancreatic cancer cells overexpress many families of 
growth factors and their receptors, including epidermal growth factor (EGF), vascular 
endothelial growth factor (VEGF), fibroblast growth factor (FGF) and its receptor and plateled-
derived growth factor (PDGF), as well as many cytokines, such as transforming growth factor 
(TGF)-β, tumor necrosis factor-α, interleukin (IL)-1, IL-6 and IL-8, which enhances mitogenesis 
(Korc, 2003; Xie et al., 2001, 2003 and 2004). Pancreatic cancer also exhibits loss of 
responsiveness to various growth-inhibitory signals, such as members of the TGF-β family 
(Korc, 2003). The disturbed production and function of growth-promoting and -inhibiting factors 
are believed to confer a tremendous survival and growth advantage to pancreatic cancer cells, as 
manifested by the development of angiogenic, invasive and metastatic phenotypes that are 
resistant to all conventional treatments. The clinical importance of the findings described above 
is underscored by numerous experimental and clinical observations (Korc, 2003). For example, 
the concomitant presence of EGF receptor (EGFR) and either EGF or TGF-β in the cancer cells 
is associated with disease progression and decreased survival. EGFR blockade with an anti-
EGFR antibody attenuates pancreatic tumor growth, and inhibition of EGFR tyrosine kinase 
activity suppresses pancreatic angiogenesis (Bruns et al., 2000). These findings are among the 
many that support the hypothesis that dysregulated production and function of growth factors has 
an important role in pancreatic cancer.  
 
3.2 The role of angiogenesis in local and systemic tumor growth 
 
3.2.1 Tumor angiogenesis 
Tumor angiogenesis is the formation of new blood vessels from existing vessels and new 
circulating endothelial progenitor cells from bone marrow (Folkman, 1990). In 1971, Folkman 
proposed that tumor growth and metastasis are angiogenesis-dependent, and hence, blocking 
angiogenesis could be a strategy to arrest tumor growth (Folkman, 2000). This possibility 
stimulated an intensive search for pro- and anti-angiogenic molecules. In 1976, Gullino showed 
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that cells in pre-cancerous tissue acquire angiogenic capacity on their way to becoming 
cancerous (Gullino, 1978). He proposed that this concept be used to design strategies to prevent 
cancer (Gullino, 1978), a hypothesis later confirmed by genetic approaches (Hanahan et al., 
2000). 
 
3.2.2 The angiogenic switch 
It is now widely accepted that the “angiogenic switch” is “off” when the effect of pro-angiogenic 
molecules is balanced by that of anti-angiogenic molecules, and is “on” when the net balance is 
tipped in favour of angiogenesis (Hanahan et al., 2000; Bouck et al., 1996). Various signals that 
trigger this switch have been discovered (Table 3.1). Pro- and anti-angiogenic molecules can 
emanate from cancer cells, endothelial cells, stromal cells, blood and the extracellular matrix 
(Fukumura et al., 1998). Their relative contribution is likely to change with tumor type and 
tumor size, tumor growth, regression and relapse.  
 
3.2.3 Formation of tumor vessels 
Tumor vessels develop by sprouting or intussusception from pre-existing vessels. Circulating 
endothelial precursors, shed from the vessel wall or mobilized from the bone marrow, can also 
contribute to tumor angiogenesis (Asahara et al., 2000; Rafii, 2000). In addition, tumor vessels 
lack protective mechanisms that normal vessels acquire during growth. For example, they may 
lack functional perivascular cells, which are needed to protect vessels against changes in oxygen 
or hormonal balance, provide them necessary vasoactive control to accommodate metabolic 
needs, and induce vascular quiescence (Benjamin et al., 1999). Finally, the vessel wall is not 
always formed by a homogenous layer of endothelial cells (Jain, 1988). Instead, it may be lined 
with only cancer cells or a mosaic of cancer and endothelial cells.  
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Activators Function 
VEGF family members Stimulate angio/vasculogenesis and permeability 
VEGFR, NRP-1 Integrate angiogenic and survival signals 
Ang1 and Tie2 Stabilize vessels, inhibit permeability 
PDGF-BB and receptors Recruit smooth muscle cells 
TGF-β and receptors Stimulate extracellular matrix production 
FGF, HGF Stimulate angiogenesis 
Integrins Receptors for matrix macromolecules and proteinases 
Plasminogen activators, MMPs Remodel matrix, release and activate growth factors 
  
  
Inhibitors Function 
VEGFR-1, soluble VEGFR-1 Sink for VEGF, VEGF-B 
Ang2 Antagonist of Ang1 
TSP-1,-2 Inhibit endothelial migration, growth, adhesion and survival 
Angiostatin Suppresses tumor angiogenesis 
Endostatin Inhibits endothelial survival and migration 
Platelet factor-4 Inhibits binding of bFGF and VEGF 
Prolactin Inhibits bFGF/VEGF 
Interferons and interleukins Inhibit endothelial migration; downregulate bFGF 
 
Table 3.1 Angiogenesis activators and inhibitors 
 
 
3.2.4 Structure and function of tumor vessels 
Tumor vessels are structurally and functionally abnormal: their walls have numerous “openings” 
and a discontinuous or absent basement membrane. In addition, the endothelial cells are 
abnormal in shape, growing on top of each other and projecting into the lumen. These defects 
make tumor vessels leaky (Hobbs et al., 1998; Hashizume et al., 2000; Dvorak et al., 1999).  
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3.3 Angiogenic phenotype of pancreatic cancer 
 
Although pancreatic cancer is not a grossly vascular tumor, it often exhibits enhanced foci of 
endothelial cell proliferation. Moreover, several (Korc, 2003; Seo et al., 2000; Linder et al., 
2001; Fujioka et al., 2001; Mirecka et al., 2001; Stipa et al., 2002; Niedergethmann et al., 2002; 
Khan et al., 2002; Kuwahara et al., 2003; Shibaji et al., 2003; Karademir et al., 2000; Ikeda et al., 
1999; Ellis et al., 1998) but not all (Fujimoto et al., 1998) studies have reported a positive 
correlation between blood vessel density and disease progression in cases of pancreatic cancer, 
supporting the important role of angiogenesis in this disease.  
At the molecular level, numerous factors have been shown to be involved in pancreatic cancer 
angiogenesis. Among this growing list of growth factors, VEGF is believed to be critical for 
pancreatic cancer angiogenesis (Korc, 2003; Xie et al., 2004). Several studies have shown that 
VEGF expression correlates with microvessel density and disease progression (Korc, 2003; Seo 
et al., 2000; Niedergethmann et al., 2002, 2000; et al., 1999; Knoll et al., 2001). Additionally, 
VEGF-c is overexpressed in pancreatic cancer and correlated with enhanced lymph node 
metastasis (Tang et al., 2001). Moreover, pancreatic cancers overexpress several other mitogenic 
growth factors that are also angiogenic, such as EGF, TGF-α, HGF, FGFs and PDGF-β (Korc, 
2003; Balaz et al., 2001). Together, these factors may produce mitogenic activity in an autocrine 
and paracrine fashion, promoting pancreatic tumor cell growth and angiogenesis and eventually 
enhancing pancreatic tumor invasion and metastasis.  
 
3.4 Therapeutic angiogenesis 
 
Inhibition of neo-angiogenesis is a new and attractive target for tumor therapy, since it 
theoretically offers the hope of long-term control of tumor progression. Antiangiogenic therapy 
offers a number of potential benefits including lack of resistance to some agents, synergistic 
interaction to other modalities, lack of significant toxicity compared with conventional agents, 
and a potent antitumor effect. Administration of angiogenesis inhibitors might keep the tumor 
and its metastases dormant (rather than killing it), and co-administration of cytotoxic drugs 
might kill it (Teicher et al., 1995; Satoh et al., 1998).  
Consistent with the roles of the factors described above, anti-angiogenic therapies have been 
demonstrated to suppress tumor growth in animal models of pancreatic cancer (Bruns et al., 
2000-2004).  
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Based on successful preclinical data, several anti-angiogenic agents alone or in combination with 
conventional therapies are now in clinical trials (Table 3.2; www.cancertrials.nci.nih.gov). 
Numerous studies have been conducted to investigate the effects of different receptor tyrosine 
kinase inhibitors (Table 3.2).  
 
Drug Mechanism 
  
Phase I  
PTK787/ZK2284 Blocks VEGF-receptor signaling 
Matuzumab EGFR1 monoclonal antibody 
Erlotinib EGFR kinase inhibitor  
Vatalanib VEGFR kinase inhibitor 
SU6668 Blocks VEGF-, FGF- and PDGF-receptor signaling 
Phase II  
Imatinib PDGFR kinase inhibitor 
Cetuximab EGFR1 monoclonal antibody 
Erlotinib EGFR kinase inhibitor  
Phase III  
SU5416 Blocks VEGF-receptor signaling 
Thalidomide Unknown 
AG3340 Synthetic MMP inhibitor 
Interferon-α Inhibition of bFGF and VEGF production 
IM862 Unknown mechanism 
Marimastat Synthetic MMP inhibitor 
 
Table 3.2 Angiogenesis inhibitors in clinical trials for cancer (including pancreatic cancer) 
 
However, as tumors grow, they begin to produce a wider array of angiogenic molecules. 
Therefore, if only one molecule (for example, VEGF) is blocked, tumors may switch to another 
molecule (for example, bFGF or IL-8). Thus we may require a cocktail of antibodies/inhibitors. 
 
Several oncogenes and their intracellular protein products such as v-src and v-ras induce the up-
regulation of angiogenic factors such as VEGF, EGF, bFGF and PDGF and increase the 
production of cytokines and proteolytic enzymes (Mukhadopathyay et al., 1995; Jiang et al., 
1997; Kerbel et al., 1998; Okada et al., 1998; Kypta et al., 1990; Arbiser et al., 1997). In this 
respect, targeting intracellular proteins might be a promising approach in angiogenesis therapy of 
pancreatic cancer.  
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3.5 Kinases of the Src family nonreceptor protein tyrosine kinases 
 
One of the potential intracellular therapeutic targets receiving considerable recent attention is 
activation of c-Src, a nonreceptor protein tyrosine kinase. In pancreatic adenocarcinomas, src is 
activated in more than 70% of primary tumors (Coppola, 2000). 
 
3.5.1 The discovery of c-Src proto-oncogene 
In 1911, Peyton Rous first described a viral agent capable of inducing tumors in chickens 
providing evidence for the transmissible nature of cancer (Rous, 1911). This seminal work went 
largely unappreciated and uncorroborated until the 1950s, when tumor cells were shown to arise 
from infection with the Rous sarcoma virus (Rubin, 1955). This finding was confirmed when 
temperature sensitive activated v-Src mutants failed to transform cells at non-permissive 
temperatures, demonstrating a requirement for the active virus in cellular transformation (Martin, 
1970). In the 1970s, Brugge and colleagues isolated and identified v-Src as the transforming 
protein of the oncogenic Rous sarcoma virus utilizing tumor bearing rabbit serum (Brugge et al., 
1977). Additional experiments demonstrated that the viral Src gene (v-Src) has a highly 
conserved and ubiquitously expressed cellular homologue, c-Src, which is present in normal 
cells (Stehelin et al., 1976). Src was not only the first proto-oncogene identified, it was also the 
first demonstrated to possess intrinsic protein kinase activity (Collett et al., 1978; Levinson et al., 
1978) spawning both a search for similar protein tyrosine kinases and investigations into the role 
of Src in regulating cellular behavior. The last two decades have witnessed an explosion in Src 
research, including the recent development of selective small molecule inhibitors that target Src.  
 
3.5.2 Src family members 
The non-receptor protein tyrosine kinase Src is the prototypical member of a kinase family that 
includes Yes, Fyn, Lyn, Lck, Hck, Fgr, Yrk, Frk and Blk. This group is collectively known as 
the Src family kinases (SFKs), and, in contrast to receptor protein tyrosine kinases (VEGFR, 
EGFR, PDGFR), is not comprised of transmembrane proteins (Neet et al., 1996).  
Tyrosine kinases catalyze the transfer of phosphate from ATP to a tyrosine residue of specific 
cell protein targets. 
 
3.5.3 Structural organization of Src proteins 
As a result of mutational studies and structural modeling based on crystallography data, the 
structure of Src has been well characterized.  
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In vertebrates the proteins of the Src family have similar structure (Brown et al., 1996). The 
proteins of this group, ranging in molecular mass from 52 to 62 kD, comprise six distinct 
functional domains (Fig. 3.1 and 3.2): Src homology domain 4 (SH4), a unique domain, SH3 
domain, SH2 domain, a catalytic domain (SH1), and a C-terminal regulatory region. 
The SH4 domain is a region containing from 15 to 17 amino acid residues which comprises 
signals for modification with fatty acids (Rech, 1993). The glycine at position 2 is myristylated, 
thus binding protein tyrosine kinase (PTK) to the cell membrane. Nonmyristylated Src molecules 
do not bind to membranes. On the other hand, some Src molecules carrying this modification can 
be found unlinked in the cytosol. Myristylation probably does not guarantee association of the 
protein with the membrane. In addition to myristylation signals, the Src SH4 domain contains 
basic amino acid residues which are substrates for post-translational palmitylation. Only 
myristylated molecules are palmitylated and consequently this process probably occurs on the 
membrane. Palmitylation is a reversible process. Regulated depalmitylation and repalmitylation  
 
 
 
Figure 3.1 Ribbon diagram illustrating the structure of human Src. Key phosphorylation sites are 
included. 
 
  Chapter 3. Introduction  
 - 18 - 
 
 
Figure 3.2 Domain structure of Src protein. Key phosphorylation sites are included. 
 
may be a mechanism for the changing of the Src family kinases localization in response to 
corresponding stimulation (Kaplan et al., 1988; Pellman et al., 1985). 
The unique domain (amino acid residues 18-84) is specific for each Src family protein. This 
region is suggested to be responsible for specific interaction of the PTK with particular receptors 
and protein targets (Thomas et al., 1997). At the same time, Src is a single member of the Src 
kinase group which is phosphorylated at Thr-34, Thr-46, and Ser-72 by a cyclin-dependent 
kinase (Cdc2) and cyclin B complex in M phase (Superti-Furga et al., 1995). The effect of this 
phosphorylation is unclear. Moreover, the unique domain contains the protein kinase C (PKC) 
binding sites – Ser-12 and Ser-48 – which are phosphorylated in the cells during PKC activation. 
The SH3 domain (amino acid residues 85-140) is necessary for interactions with protein 
substrates and it also ensures the intramolecular bindings controlling catalytic activity, protein 
localization in the cell, and association with protein targets (Pawson, 1995). The SH3 domain of 
Src has a globular structure, one side of which is slightly hydrophobic and contains a cluster of 
acidic residues. This domain binds to the proline-rich regions of PTK substrates. All known SH3 
ligands carry a consensus sequence PXXP. Amino acid residues adjacent to pro-line determine 
specificity of SH3 domains (Riskles et al., 1995). The SH3 ligands may bind to this domain both 
in NH2–COOH and COOH–NH2 orientation (Yu et al., 1994). 
The SH3 sequences as well as the SH2 and the catalytic domains shown below, have been found 
in cellular proteins of different classes. 
The SH2 domain is a second modulating region (amino acid residues 141-260), which controls 
the range of proteins interacting with the Src family kinases. The SH2 domains of different PTK 
recognize a short amino acid sequence carrying phosphotyrosine. From three to five amino acid 
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residues following tyrosine determine the specificity of individual SH2 domains (Songyang et 
al., 1993). In kinases of the Src family this region is more conserved than the SH3 domain and 
can be tightly bound with specific proteins phosphorylated by tyrosine. The SH2 domains of Src 
and Lck kinases carry deep hydrophobic pockets for interactions of amino acid Ile at position pY 
+ 3. Some proteins interacting with Src contain an optimum binding structure, pYEEI. However, 
not all proteins binding to the SH2 domain of Src possess such phosphorylated sequence. 
A mutation in the SH2 domain in the region of amino acid residues from 142 to 169 leads to cell 
transformation (Raymond et al., 1987). This mutation probably affects Src binding to substrates, 
cytoskeletal proteins in particular (see below). 
The kinase domain (amino acid residues 265-516) is found in all proteins of the Src family as 
well as in other PTK. It is responsible for tyrosine kinase activity and plays a crucial role in 
substrate specificity (Hesketh, 1995). Certain amino acid residues within this domain are 
identical in all kinases and involved in ATP binding and the phosphotransferase reaction 
(Hughes, 1996). 
The kinases of the Src family may bind some substrates after phosphorylation, thus promoting 
phosphorylation of other sequences of one or several neighboring substrate molecules (Mayer et 
al., 1995). A strict specificity towards Tyr but not towards Ser or Thr is due to the close 
proximity of a conserved loop present in all tyrosine kinases (FP425IKWTA in Src) to the main 
chain of the substrate. Proline facilitates binding to the phenylalanine ring of tyrosine, but is 
ineffective in binding substrates carrying serine or threonine. 
Phosphorylation of Tyr-416 stimulates complete activation of Src and provides a binding site for 
SH2 domains of other cellular proteins. The elimination of Leu-516, highly conserved in all 
protein tyrosine kinases and located in the catalytic domain, interferes with the transforming 
activity of p60 v-Src (Yaciuk et al., 1986). 
The C-terminal region (amino acid residues from 517 to ~536) plays a significant role in 
regulation of Src kinase activity. All kinases of the Src family have a C-terminal region of 15-19 
amino acid residues with tyrosine at the constant position surrounded by conserved amino acids 
(Tyr-527 in Src). It has been shown that elimination of phosphotyrosine from the normal Src 
increases its kinase activity (Schwartzberg, 1998). Phosphorylation of the C-terminal Tyr 
inhibits kinase activity by more than 98% and suppresses all stimulating effects caused by 
phosphorylation of Tyr-416 in the catalytic domain (Van Hoek et al., 1997). 
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3.5.4 Structural differences between v-Src and c-Src proteins 
The main difference between v-Src and c-Src is found in the structure of their C-terminal regions 
(Fig. 3.3). The last “tail” 19 amino acids of c-Src contain Tyr-527, which plays a regulatory role 
controlling kinase activity (Yaciuk et al., 1986; Dorai et al., 1991). In v-Src these 19 amino acids 
are replaced by 12 amino acids present in all known RSV strains. The only exception is v-SrcLM 
whose atypical structure is associated with a decreased metastatic potential of transformed cells 
(Tatosyan et al., 1996). It has been recently demonstrated that in metastases of human colon 
cancer, the c-Src protein has mutations just in this region. It should be mentioned that now this is 
the most reliable example of the role of mutations in the src gene in human carcinogenesis (Irby 
et al., 1999). 
 
 
 
Figure 3.3 Domain structure of cellular (c-) and viral (v-) Src 
 
 
3.5.5 Regulation of Src kinases 
The SH2 and SH3 domains play a key role in regulation of catalytic activity of the Src family 
kinases. X-Ray analysis has demonstrated how intramolecular interactions between SH2 and 
SH3 domains stabilize inactive conformational structure of Src kinases. Both domains are 
adjacent to the kinase domain from the side opposite to the catalytic cleft. The SH3 domain 
interacts with the catalytic domain and linker sequences located between SH2 and catalytic 
domains (Fig. 4) (Xu et al., 1999). The SH2 domain interacts with phosphotyrosine at position 
527 localized in the C-terminal region of the protein. Tyr-527 in c-Src, as well as the 
corresponding tyrosine residues in other PTK are the primary phosphorylation sites in vivo. This 
base is phosphorylated by the cytoplasmic kinase Csk (Nada et al., 1991). The loss of Tyr-527 or 
its dephosphorylation leads to stimulation of Src catalytic activity. This conclusion is based on a 
number of experimental data: the substitution of Tyr-527 by another amino acid residue 
constitutively activates c-Src (Kmiecik et al., 1987); this region is absent from the v-Src protein 
(Reynolds et al., 1987); the inhibition of the csk gene activity stimulates activity of PTK of the 
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Src family (Imamoto et al., 1993). Therefore, it has been suggested that phosphorylation of the 
C-terminal tyrosine by Csk kinase provides intramolecular interaction of this region with the 
SH2 domain thus preserves the Src protein in a closed inactive form. 
Mutations in the SH3 domain also lead to activation of Src kinases, although the role of the SH3 
domain in inhibition of protein enzymatic activity is obscure. The kinase domain apparently 
remains accessible even in “closed” conformation, namely, when the SH2 domain is associated 
with phosphotyrosine at position 527 (Fig. 3.4). The SH3 domain forms an independent 
intramolecular contact with the N-terminal fragment of the kinase domain. Accordingly, kinase 
inactivation may result from the formation of a rigid structure stabilized by double bonds 
between the SH2 and SH3 domains and the catalytic region of the protein. Such structure 
prevents any movement inside the kinase domain. Mutations in any of the interacting regions of 
the Src protein disrupt the rigid structure of the molecule; this, in turn, destabilizes other 
intramolecular interactions. Consequently, both the SH2 and SH3 domains regulate kinase 
activity by intramolecular contacts. Abnormal interactions may be the main activation  
 
 
 
Figure 3.4 Regulation of Src activity: 
a) Closed autoinhibited state;  
b) Open intermediate state induced either by interactions of the SH3 and SH2 domains 
with the Src protein partners or by dephosphorylation of the C-terminal Tyr-527. This 
makes Tyr-416 accessible for phosphorylation;  
c) Open activated form with phosphorylated Tyr-416 
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mechanism of the Src proteins. It cannot be excluded that these domains play a similar role in 
regulation of kinase activity in proteins that lack phosphotyrosine in the C-terminal region (Fps, 
Abl) (Pawson et al., 1992). It should be noted that the above-mentioned mechanism not only 
precisely regulates kinase activity of the Src proteins, but controls the interactions of SH2 and 
SH3 domains with other molecules, thus providing different levels of Src regulation. 
As shown above, the regulation of Src activity occurs at two sites, the modification of each of 
them leads to opposite results. The phosphorylation of Tyr-416 in the activating loop of the 
kinase domain activates the enzyme, while the phosphorylation of the C-terminal Tyr-527 causes 
its inactivation. Different regulatory elements controlling Src activity affect only particular 
regions in the kinase domain. These effectors contain amino acid residues involved in catalysis 
or substrate binding (Sichei et al., 1997). They may be the activating loop (amino acid residues 
404-432), the catalytic loop (the region around the amino acid at position 382), and the C-helix 
(the region around the amino acid at position 310). The modulation of their position and 
conformation by phosphorylation and interaction with regulatory subunits may control catalytic 
activity. 
In vivo the Src kinase can be phosphorylated only at one of two tyrosine residues. The model for 
Src tyrosine kinase activation includes three subsequent stages (Fig. 3.4). 
The activating loop plays a central role in regulating kinase activity. Its phosphorylation at Tyr-
416 in Src (or homologous amino acid residues in other tyrosine kinases) is necessary for 
complete activation of most kinases studied so far. In the absence of phosphorylation, the 
activating loop acquires different conformations, which often inhibit protein–protein 
interactions. A nonphosphorylated activating loop can inhibit kinase activity either directly, 
disturbing the region involved in activation, or indirectly, conferring a specific conformation, 
which prevents substrate binding. Conversely, in the phosphorylated state, the conformation of 
the activating loop is similar in all known kinases. In this active conformation the loop forms a 
part of the site recognized by the substrates (Xu et al., 1997). 
 
3.5.6 Src substrates 
The proteins tyrosine phosphorylated as a result of src gene function are briefly summarized in 
Table 3.3.   
 
3.5.7 Role of Src in regulation of cellular processes 
c-Src is a multifunctional protein involved in the regulation of a variety of normal processes, 
including proliferation, differentiation, survival, motility, angiogenesis, and functions of fully 
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differentiated cells (Thomas and Brugge, 1997). To carry out these activities, c-Src interacts with 
numerous cellular factors, including cell surface receptors (EGF family, CSF-1, PDGF, and FGF 
receptors, as well as integrins, cell-cell adhesion molecules, etc. [Biscardi et al., 2000; Irby and 
Yeatman, 2000; Owens et al., 2000; Moro et al., 2002]), steroid hormone receptors (Migliaccio 
et al., 1996, 2000; Boonyaratanakornkit et al., 2001), components of pathways regulated by 
heterotrimeric G proteins (Luttrell et al., 1999; Ma et al., 2000), STATs (Silva et al., 2003), focal 
adhesion kinase (FAK) (Kaplan et al., 1994), the adaptor proteins p130Cas (Burnham et al., 
2000) and Shc (Sato et al., 2002), and many others. Each of these partners represents a different 
class of proteins and functions in unique signaling pathways for       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3 Target proteins for Src kinases 
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which the molecular nature and biological consequences of the interactions with c-Src have been 
investigated. The interactions between c-Src and other molecules can be found in Figure 3.5. Src 
is also implicated in invasion and angiogenesis, the latter property of which will be extensively 
discussed below (3.7).  
 
 
 
 
Figure 3.5 c-Src is a protein involved in the regulation of a variety of biological processes, including 
proliferation, differentiation, survival, motility, angiogenesis, and functions of fully differentiated 
cells. 
RTK, receptor tyrosine kinase; PI3K, phosphatidylinositol 3-kinase; STAT3, signal transducers 
and activators of transcription 3; IKK, InB kinase; MAPK, mitogen-activated protein kinase; 
MEK, mitogen-activated protein kinase kinase; ERK, extracellular signal-regulated kinase; NF-
κB, nuclear factor-κB; FAK, focal adhesion kinase.  
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3.6 Src activation and tumor progression 
 
The likely regulators, or types of regulation, which can lead to Src’s conformational “opening” 
and activation that might occur in cancer cells are shown in Figure 3.6.  
 
 
 
Figure 3.6 Regulation of Src activity in tumor cells 
 
The relationship between Src activation and cancer progression appears to be significant. The 
evidence underlying this hypothesis is largely based on the observation that both Src protein 
levels and, to a greater degree, Src protein kinase activity, are frequently elevated in human 
neoplastic tissues when compared to adjacent normal tissues. Moreover, these levels appear to 
increase with the stage of disease. Similarly, increased Src protein kinase activity has been 
observed in numerous human cancer cell lines derived from these tumors. 
Src kinase activity, from 4 – 20-fold higher than normal tissues, has been found in human 
mammary carcinomas (Egan et al., 1999; Jacobs and Rubsamen, 1983; Muthuswamy et al., 
1994; Verbeek et al., 1996). Similarly, cell lines derived from these tumors display up to a 30-
fold elevation in Src activity. 
The c-Src proto-oncogene has frequently been implicated in the initiation and progression of 
human colon cancer (Bolen et al., 1987a; Cartwright et al., 1989, 1990, 1994; Weber et al., 
1992). Src activity is increased 5 – 8-fold in the majority of colon tumors.  
Elevated Src protein levels and/or kinase activity has been reported in lung (50 – 80%) 
(Mazurenko et al., 1992), neural (23/27 neuroblastomas, 3/3 retinoblastomas) (Bjelfman et al., 
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1990; Bolen et al., 1985), ovarian (Budde et al., 1994; Wiener et al., 1999), esophageal (3 – 4-
fold increases in activity in Barrett’s esophagus and 6-fold elevations in adenocarcinomas) 
(Kumble et al., 1997) and gastric cancers (Takeshima et al., 1991), as well as melanoma (Bjorge 
et al., 1996) and Kaposi’s sarcoma (Munshi et al., 2000).  
Src activity has recently been studied in pancreatic cancer. Lutz et al. (1998) examined 
pancreatic ductal carcimonas as well as pancreatic cell lines for elevated Src protein levels and 
kinase activity. Src protein levels were elevated in 13/13 pancreatic cancers and in 14/17 
pancreatic cell lines. Kinase activity was only detectable in cancer cells and this activity did not 
correlate with either the c-Src or Csk protein levels. 
 
3.7 Src and tumor angiogenesis 
 
There is a significant amount of data supporting the influence of Src on tumor angiogenesis and 
metastasis.  
Src activation is required for hypoxia-mediated expression of VEGF (Mukhopadhyay et al., 
1995). More recently, Trevino et al. (2005) have shown that Src regulates both constitutive and 
growth factor-induced VEGF and interleukin-8 expression and that Src activation up-regulates 
VEGF mRNA transcription by activation of signal transducers and activators of transcription 3, 
which forms a complex with hypoxia-inducible factor-1 and other factors on the VEGF promoter 
(Gray et al., 2005). The experiments by Ellis et al. (1998) demonstrated that antisense Src 
strategy was effective in reducing both constitutive and hypoxic-induced VEGF production in a 
human colon carcinoma cell line. In addition, how Src links between VEGF stimulation and the 
control of cell survival remains to be determined. It has been shown that receptor tyrosine 
kinases activate Src by autophosphorylation of tyrosine residues that function as docking sites 
for the SH2 domain of Src kinases on the receptor itself or by phosphorylation of docking 
proteins. Binding of the SH2 domain of Src to tyrosine phosphorylation site on VEGFR or on a 
docking protein releases Src from the autoinhibited state and enables the catalytic activity to be 
stimulated by autophosphorylation of a key tyrosine residue in the activation loop of the catalytic 
core. Once activated, Src could link VEGF-stimulation with the PDK/PKB signaling cassette 
leading to stimulation of endothelial cell survival and angiogenesis.  
There is also evidence that Src cooperates with the EGFR in growth signaling (Roche et al., 
1995; Wilson et al., 1989). Fibroblasts that overexpress Src display an enhanced mitogenic 
response to EGF, an effect that is independent on Src’s myristylation and catalytic activity 
(Luttrell et al., 1988). However, the molecular understanding of synergy between Src and the 
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EGFR in mitogenic signaling is much less advanced than for PDGFR (Mori et al., 1993; Broome 
et al., 1999; Stover et al., 1996), although it seems likely that Src and activated EGFR form a 
complex and that EGF induces Src activation (Biscardi et al., 1999). 
Further, Karni et al. have demonstrated the ability of constitutively active Src to induce HIF-
1alpha under normoxic conditions (Karni et al., 2002) suggesting that Src activation, regardless 
of mechanism, can augment VEGF production and angiogenesis. Ongoing work from this 
laboratory has demonstrated a role for Src in regulating VEGF expression in other tumor types 
including pancreatic cancer, where Src activation of the PI3kinase/Akt signaling pathway is 
required (Summy et al., 2006). As Src is a regulator of multiple signal transduction pathways, it 
should not be surprising that Src is important in regulating other pro-angiogenic factors such as 
bFGF, and IL-8.  
In addition to regulating VEGF and bFGF expression, Src regulates responses to these factors in 
both tumor and endothelial cells. Elicieri and co-workers have shown both bFGF and VEGF are 
able to induce Src activation in avian endothelial cells (Elicieri et al., 1999). Additionally, 
overexpression of the dominant negative Src induces apoptotic cell death in the VEGF-treated 
endothelial cells suggesting a survival function for Src during VEGF-induced angiogenesis. 
Similar results were obtained when utilizing a virus that encodes Csk, a protein tyrosine kinase 
that inhibits Src activity by phosphorylating Tyr-530 in the c-terminal tail.  
Overexpression of a kinase-inactive Src also resulted in reduced phosphorylation of paxillin and 
cortactin, suggesting a role for Src in actin cytoskeletal rearrangement and migration (Kilarski et 
al., 2003).  
As in tumor cells, activated Src promotes a mesenchymal-like phenotype in endothelial cells, 
increasing migratory potential of these cells as well (Potter et al., 2005). 
There is convincing evidence that the linked activities of Src and focal adhesion kinase (FAK) 
control cell migration. In support of a role for Src, cells expressing kinase-defective v-Src have 
enlarged focal adhesions and their migration is suppressed (Fincham et al., 1998). Src and FAK 
co-localize at integrin adhesion sites and cooperate with growth factor receptors, such as EGF 
and PDGF to induce signaling pathways that control diverse aspects of cell behavior, including 
growth, survival and migration (Figure 3.7).  
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Figure 3.7 Src, FAK and adhesion turnover during fibroblast migration (Frame, 2002) 
 
Current results suggest Src activation in tumor cells indirectly regulates Src activity in 
endothelial cells. Increased Src activity in the tumor cells increases VEGF expression, resulting 
in increased binding to VEGF receptors on endothelial cells. This process then leads to 
association of Src with these receptors, increasing Src activity in endothelial cells as well. This 
continuing cycle promotes Src-mediated increases in migratory potential and permeability of 
endothelial cells and facilitates tumor cell extravasation (Figure 3.8). The importance of 
targeting tumor-associated endothelial cells for therapeutic efficacy has been highlighted from 
recent work on inhibitors of receptor tyrosine kinases in clinical trial (Table 3.2) (Yokoi et al., 
2005; Thaker et al., 2005; Yazici et al., 2005; Lev et al., 2005, Yigitbasi et al., 2004). Inhibitors 
of Src thus have the potential to interfere with this cycle by affecting biological functions in both 
tumor and tumor-associated endothelial cells that contribute to metastasis.  
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Figure 3.8 Model by which Src activity mediates biologic functioning of tumor cells and 
endothelial cells, and promotes intercellular signaling to promote tumor progression and 
metastasis. * Indicates the signaling molecules and/or cellular functions potentially affected by 
Src kinase inhibition. 
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Chapter 4 
 
THESIS PROPOSAL 
               
 
 
The prevalence of activated Src in cancer indicates that this protein plays a significant role in the 
progression of many cancers, but since all of them (and specially pancreatic cancer) are 
angiogenesis dependent, the main goal of the work described in this thesis was to demonstrate 
the role of Src family protein kinases in pancreatic tumor progression with special emphasis on 
angiogenic regulation, and how Src inhibitors may affect this process (Figure 4). 
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Figure 4 Thesis proposal: inhibition of Src tyrosine kinase as an anti-angiogenic therapy of 
human pancreatic cancer 
 
 
  Chapter 5. Materials and methods  
 - 31 - 
Chapter 5 
 
MATERIALS AND METHODS 
               
 
5.1 Materials          33 
5.1.1 Laboratory equipment       33 
5.1.2 Chemical reagents and other research solutions    34 
5.1.3 Drugs          35 
5.1.4 Cell lines         36 
5.1.5 Media and supplements       38 
5.1.6 Growth factors        39 
5.1.7 Kits and other research products      39 
5.1.8 Antibodies         40 
5.1.9 Animals for in vivo experiments      40 
5.1.10 Materials used for in vivo studies      40 
5.1.11 Software         41 
5.1.12 Buffers         41 
5.2 Methods          45 
5.2.1 Cell biological methods       45 
5.2.1.1   Cell culture techniques      45 
5.2.1.2   Cell quantification and evaluation of viability   46 
5.2.1.3   Cell stimulation with different factors    46 
5.2.1.4   Storage of cells       46 
5.2.1.5   Detection of viable cells      47 
5.2.1.6   Inhibition of growth factor-mediated proliferation  48 
5.2.1.7   Chemotaxis assay       48 
5.2.2 Biochemical methods        49 
 5.2.2.1   Inhibition of protease activity     49 
 5.2.2.2   Preparation of cellular extracts using RIPA buffer   49 
 5.2.2.3   Determination of protein concentration    49 
  Chapter 5. Materials and methods  
 - 32 - 
 5.2.2.4   Immunoprecipitation of proteins     50 
 5.2.2.5   SDS-Polyacrylamidgelelectrophoresis PAGE   50 
 5.2.2.6   Transfer of proteins to PVDF membrane    51 
 5.2.2.7   Ponceau S staining of proteins on PVDF membrane  52 
 5.2.2.8   Analysis of proteins on PVDF membrane 
 by immunoblotting       52 
   5.2.2.9   Stripping and re-probing of western blot    53 
5.2.3 Determination of apoptotic cells by FACS analysis 
via propidium iodide staining      53 
5.2.4 Enzyme-linked immunoassays      53 
5.2.4.1   Determination of human vascular endothelial growth 
  factor concentrations in cell culture supernates   53 
5.2.4.2   In vitro Src kinase inhibition test     54 
5.2.5 In vitro study of angiogenesis      55 
 5.2.5.1    Aortic ring assay       55 
 5.2.5.2    Spheroid angiogenesis assay     55 
5.2.6 Orthotopic xenograft pancreatic tumor model    56 
5.2.6.1   Tumor cell implantation      56 
5.2.6.2   Treatment of established tumors growing  
  in the pancreas of nude mice     58 
5.2.6.3   In vivo evaluation of plasma concentration 
  levels of AZM475271      58 
5.2.6.4   Monitoring of mouse body weight and tumor volume  58 
5.2.6.5   Necropsy procedure and histopathological studies  58 
5.2.7 Immunohistochemical analyses      59 
5.2.7.1   Immunohistochemistry of paraffin embedded tissues  59 
5.2.7.1.1    Haematoxylin and Eosin staining   59 
5.2.7.1.2 Staining for Ki-67 antigen (The assessment 
        of cell proliferation)     59 
5.2.7.2   Immunohistochemistry of snap-frozen tissues   60 
5.2.7.2.1 Terminal deoxynucleotidyl transferase– 
        mediated nick end labeling (TUNEL) staining  60 
5.2.7.2.2    Staining for CD31     61 
5.2.7.2.3 Immunofluorescence double staining 
  Chapter 5. Materials and methods  
 - 33 - 
        for CD31 and TUNEL     61 
5.2.8 Statistical analysis        62 
 
5.1  Materials 
 
5.1.1 Laboratory equipment 
 0.45 µm sterile filters     BD Falcon, France 
 –20ºC Freezer      Siemens AG, Germany   
 4ºC Fridge      Siemens AG, Germany 
 5 ml FACS tubes     BD Biosciences, Belgium  
 –80ºC Freezer      Heraeus, Hanau, Germany 
 Automatic pipettes     Gilson, Middleton, WI, USA 
 AxioCam MRc5 camera    Carl Zeiss GmbH, Germany 
 Blotting chamber     Bio-rad, Munich, Germany 
 BD Biocoat™ Matrigel invasion chamber  BD Biosciences, Belgium 
 Cell counting chambers    Bürker-Türk, Germany 
 Centrifuges      Eppendorf, Germany 
 CO2 Incubators     Heraeus, Rodenbach, Germany 
 Digital Precision Scale    KERN & Sohn GmbH, Germany 
 Embedding cassettes     Leica Microsystems GmbH, Germany 
 Fluorescence-activated cell sorter (FACS)  Becton Dickinson, USA 
 Gel electrophoresis systems    Bio-rad, Munich, Germany 
 Heating block      Biometra, Germany 
 Hybond-P membrane     Amersham Biosciences, Germany 
 Hyperfilm      Amersham Biosciences, Germany 
 Kinetic microplate reader    υ max, USA    
 Laminar flow hoods     Heraeus, Hanau, Germany 
 Liquid nitrogen tank     MVE, New Prague, MN, USA 
 Microscopes      Carl Zeiss GmbH, Germany 
 pH-meter      WTW, Weilheim, Germany 
 Positively-charged superfrost slides   Menzel-Glaeser, Germany  
 Rocking Platforms     Biometra GmbH, Göttingen, Germany 
 Rotary microtome     Leica Microsystems GmbH, Germany 
 Semi-Dry Electrophoretic Transfer Cell  Bio-rad, Munich, Germany   
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 Sterile cell scrapers     TPP, Switzerland 
 Sterile cryotube vials     TPP, Switzerland 
 Sterile tissue culture plastic flasks and plates NUNC, Denmark 
 Sterile tissue culture plastic tubes, dishes, pipets TPP, Switzerland 
 Tissue embedding console system   Sakura, Torrance, CA, USA  
 Vortex       IKA Works, Wilmington, NC, USA 
 Water bath      GFL, Burgwedel, Germany 
 X-ray film developing machine   AGFA, Germany 
 
5.1.2 Chemical reagents and other research solutions 
 2-Mercaptoethanol     Merck, Darmstadt, Germany 
 3,3′,5,5′-Tetramethylbenzidine tablets (TMB) Sigma-Aldrich GmbH, Germany 
 30% Acrylamide/Bis Solution   Roth, Karlsruhe, Germany 
 4',6-diamino-2-phenylindole (DAPI)  Molecular Probes, USA  
 D,1-Dithiothreitol (DTT)    Sigma-Aldrich GmbH, Germany 
 Acetic acid 96%     Sigma-Aldrich GmbH, Germany 
 Ammonium Persulfate    Sigma-Aldrich GmbH, Germany 
 Aprotinin      Roche Diagnostics GmbH, Germany 
 ATP       Sigma-Aldrich GmbH, Germany   
 Bovine serumalbumin (BSA)   Sigma-Aldrich GmbH, Germany 
 Dimethylsulfoxide (DMSO)    Sigma-Aldrich GmbH, Germany
 EDTA       Sigma-Aldrich GmbH, Germany
 Protein G Sepharose 4 fast flow   Amersham Biosciences, Germany 
 Ethanol      Merck, Darmstadt, Germany  
 Glycerol      Merck, Darmstadt, Germany 
 Glycine for electrophoresis    Merck, Darmstadt, Germany 
 HEPES      NeoLab GmbH, Germany 
 Isopropanol      Merck, Darmstadt, Germany   
 Leupeptin A      Roche Diagnostics GmbH, Germany 
 Magnesium Chloride     Merck, Darmstadt, Germany 
 Methanol      Merck, Darmstadt, Germany 
 Nonidet P-40      Roche Diagnostics GmbH, Germany 
 Phenylmethylsulfonyl fluoride (PMSF)  Sigma-Aldrich GmbH, Germany 
 Phosphate citrate buffer with Sodium Perborate Sigma-Aldrich GmbH, Germany 
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 Poly (Glu, Tyr) sodium salt    Sigma-Aldrich GmbH, Germany 
 Ponceau S      Sigma-Aldrich GmbH, Germany 
 Pre-stained protein ladder    Invitrogen Corporation, Germany 
 Protease inhibitor cocktail tablets   Roche Diagnostics GmbH, Germany 
 Skim milk powder (blotting grade)   Sigma-Aldrich GmbH, Germany 
 Sodium Chloride     Merck, Darmstadt, Germany 
 Sodium Citrate     Sigma-Aldrich GmbH, Germany 
 Sodium Hydroxide     Sigma-Aldrich GmbH, Germany 
 Sodium Vanadate     Sigma-Aldrich GmbH, Germany 
 Sodiumdodecylsulfat (SDS)    Biorad, Munich, Germany 
 Sulphuric Acid     Merck, Darmstadt, Germany 
 Tetramethylethylendiamine (TEMED)  ICN Biomedicals Inc, Aurora, USA 
 Tris base      Sigma-Aldrich GmbH, Germany 
 Triton-X100      Sigma-Aldrich GmbH, Germany 
 Propidium Iodide     Sigma-Aldrich GmbH, Germany 
 Human fibronectin     Sigma-Aldrich GmbH, Germany 
 Trypan blue      Serva, Heidelberg, Germany 
 Tween 20      Merck, Darmstadt, Germany  
 Water for molecular biology    Maxim Biotech GmbH, Germany  
 Xylene      Merck, Darmstadt, Germany 
  
5.1.3 Drugs 
AZM475271 (Scheme 5.1) is a novel anilinoquinazoline inhibitor of c-Src. AZM475271 was 
synthesized and kindly provided by AstraZeneca Pharmaceuticals (Macclesfield, United 
Kingdom). For in vivo administration, AZM475271 was dissolved in Tween 20 diluted 1:100 in 
NaCl, for in vitro applications the AZM475271 stock was prepared in DMSO and stored at + 
4°C.  
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Scheme 5.1 Structure of the novel anilinoquinazoline inhibitor of c-Src AZM475271 
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4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2, Calbiochem, San 
Diego, CA, USA) is a potent and selective inhibitor of the Src family of tyrosine kinases that is 
similar to PP1. For in vitro studies PP2 (Scheme 5.2) was used as a comparable 
chemotherapeutic agent. PP2 was supplied as a 3.33 mmol/L stock in DMSO and stored at + 
4°C.  
 
 
 
Scheme 5.2 Structure of the selective inhibitor of the Src family of protein tyrosine kinases PP2 
 
5.1.4 Cell lines  
 
Human highly metastatic pancreatic carcinoma cell line L3.6pl 
For our in vivo and in vitro experiments we used variants of a human pancreatic adenocarcinoma 
cell line COLO 357. This cell line derived from a celiac axis lymph node that was partially 
replaced by neoplastic foci of well differentiated mucin-containing pancreatic ducts and it was 
originally isolated 1980 by a group from Colorado Morgan et al.  
For in vivo selection of highly metastatic human pancreatic cancer cells, we injected cells from 
the original fast growing, low metastatic FG cell line derived from COLO 357 into the pancreas 
of nude mice. To produce liver lesions, human pancreatic cancer cells implanted into the 
pancreas must complete all the steps of the process. The lesions then are designated as 
spontaneous metastases. Spontaneous liver metastases were then harvested, established in tissue 
culture, and designated as L3.4pl. Cells harvested from these cultures were injected into the 
pancreas of another set of nude mice. Liver lesions were again isolated and cells were 
established in culture. After three such selection cycles, the cell line L3.6pl was established in 
culture (Fig. 5.1). Cytogenetic analysis confirmed the human origin of the cells.  
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Figure 5.1 In vivo selection of metastatic human pancreatic cancer cells 
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The highly metastatic cell line L3.6pl showed an aggressive primary tumor growth in nude mice 
with spontaneous liver metastases (50% of animals) and spontaneous lymph nodes metastases 
(100% of animals), 50% of animals bearing L3.6pl cancer died after 36 days, whereas more then 
60% of animals after the injection of parental FG cell line survived up to 100 days (Fig. 5.2). 
L3.6pl cells produced pro-angiogenetic factors such as VEGF, bFGF, as well as IL-8 and tumor 
samples presented with a high amount of microvascularisation. In vitro studies, IHC analyses 
and in situ hybridization of tumor samples showed a significantly low expression of E-cadherine 
and MMP-9/2 level in L3.6pl cells in contrast to the parental cell line (Bruns et al., 1999). 
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Figure 5.2 Kaplan-Meier survival test 
 
Human umbilical vein endothelial cells (HUVECs) 
 
HUVECs were purchased from PromoCell (PromoCell GmbH, Heidelberg, Germany). 
 
5.1.5 Media and supplements 
 
 10-fold trypsin-EDTA    Biochrom AG, Berlin, Germany 
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 10-fold vitamin solution    Biochrom AG, Berlin, Germany 
 Ampicillin      Gibco Invitrogen, Germany 
 Dulbecco´s Modified Eagle Medium (D-MEM) Gibco Invitrogen, Germany 
 Endothelial Cell Growth Medium   PromoCell GmbH, Germany 
 Fetal Bovine Serum (FBS)    Biochrom AG, Berlin, Germany 
 Fetal Calf Serum     PromoCell GmbH, Germany 
 Human fibronectin     Sigma-Aldrich GmbH, Germany 
 Kanamycin      Gibco Invitrogen, Germany  
 L-Glutamin      Biochrom AG, Berlin, Germany 
 Nonessential amino acids (10-fold solution)  Biochrom AG, Berlin, Germany 
 Penicillin-streptomycin mixture   Biochrom AG, Berlin, Germany 
 Sodium Pyruvate     Gibco Invitrogen, Germany 
 
5.1.5 Growth factors  
 
bFGF       PromoCell GmbH, Germany 
ECGS/H      PromoCell GmbH, Germany 
Human recombinant EGF    R&D Systems, Wiesbaden, Germany 
Human recombinant VEGF165    R&D Systems, Wiesbaden, Germany 
Hydrocortison      PromoCell GmbH, Germany 
PDGF       PromoCell GmbH, Germany 
 
5.1.6 Kits and other research products 
   
Avidin-biotinylated Horseradish  
Peroxidase Complex (ABC Kit)   Vector Laboratories, CA, USA 
BCA™ Protein Assay Reagent Kit   Pierce, Rockford, USA  
DeadEnd™ Fluorometric TUNEL System  Promega, Madison, WS, USA 
ECL® Western Blotting Detection System   Amersham Biosciences, Germany 
Enhanced Chemiluminescence System   Amersham Biosciences, UK 
Human VEGF Immunoassay Kit   R&D Systems, Minneapolis, MN, USA 
Immunoprecipitation Kit    Sigma-Aldrich GmbH, Germany 
Restore™ Western Blot Stripping Buffer  Pierce, Rockford, IL, USA 
TACS MTT Cell Proliferation and  
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Viability Assay Kit     R&D Systems, Minneapolis, MN, USA 
 
 
5.1.8 Antibodies  
  
 Anti-FAK monoclonal    Cell Signaling Inc., Germany 
Anti–phospho-tyrosine monoclonal, HRP   Santa Cruz Biotechnology, CA, USA 
Anti-pTyr 576/577 FAK monoclonal  Cell Signaling Inc., Germany 
Anti-ß-actin monoclonal    Sigma-Aldrich GmbH, Germany 
Anti-v-src (Ab-1) monoclonal    Oncogene, San Diego, CA, USA  
CD31/PECAM-1 rat anti-mouse monoclonal Pharmingen, San Diego, CA, USA 
 Goat anti-rabbit polyclonal, biotinylated  Vector Laboratories, CA, USA 
 Goat anti–rabbit, HRP     Amersham, Freiburg, Germany 
Ki-67-specific rabbit anti-human polyclonal   Zymed GmbH, Germany  
 Rabbit anti-rat polyclonal, HRP   DAKO, Germany 
      
5.1.9 Animals for in vivo experiments 
 
Male immunodeficient Balb/c nu/nu mice were purchased from Charles River Laboratories 
(Sulzfeld, Germany). The mice were housed and maintained in laminar flow cabinets under 
specific-pathogen-free conditions in facilities of Institute for Surgical Research (Munich, 
Germany). The mice were quarantined during the acclimatization period of at least a week. Food 
(Standard 1320 and 1430; Altromin, Lange, Germany) and acidified water (pH 2.5-3.0) were 
available ad libitum. Regular health checks were done. The mice were used in accordance with 
institutional guidelines when they were 8-12 week of age.  
Male ACI rats were purchased from Harlan Winkelmann GmbH (Borchen, Germany). The rats 
were kept at two per cage under climatized conditions and were given standard food (Standard 
1320 and 1430; Altromin, Lange, Germany) and water ad libitum. The rats were used in 
accordance with institutional guidelines when they were 6-8 weeks old. 
All procedures were performed in accordance with current regulations and standards of the 
animal protect orders. 
 
5.1.10 Materials used for in vivo studies  
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Atropine Sulfate     Braun AG, Germany 
 Cotton applicators     NOBA Verbandmittel GmbH, Germany 
 Cutasept® F      Bode Chemie, Hamburg, Germany 
 Disposable scalpels     Feather Safety Razor Co., Japan   
 Gauze swabs      NOBA Verbandmittel GmbH, Germany 
Ketavet      Pfizer Pharmacia GmbH, Germany 
Mouse gavage feeding needle   Kent Scientific, Torrington, USA 
Pushbutton-controlled dispensing device  Hamilton Syringe Company, USA 
 Sodium Chloride Solution    Braun AG, Germany 
 Suture material     Braun AG, Germany 
Syringes, needles     BD Biosciences, Spain 
Xylazin (Rompun), 2%    Bayer HealthCare, Germany 
 
5.1.11 Software     
 
Adobe Acrobat 5.0     Adobe Systems Inc., USA 
Adobe Acrobat Distiller 5.0    Adobe Systems Inc., USA 
Adobe Photoshop 5.0     Adobe Systems Inc., USA 
AxioVision 4.4     Carl Zeiss GmbH, Germany  
SOFTmax 2.32     Molecular Devices Corp., USA 
Cellquest Pro      Beckton Dickinson, USA 
Image2PDF 1.4.5     Verypdf.com Inc., USA 
ImageJ 1.33u      NIH 
InStat 3.0      Graphpad Software, USA 
Microsoft Office 2002    Microsoft Corporation, USA 
Origin 6.0      Microcal Software Inc., USA 
SPSS 8.0      SPSS STATISTICS Inc., USA 
Windows XP Professional    Microsoft Corporation, USA 
WinMDI 2.8       Joseph Trotter 
 
5.1.12 Buffers 
 
PBS Wash Buffer, 1X 
 140 mM  NaCl 
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 2.7 mM  KCl 
 10 mM  Na2HPO4 
 1.8 mM  KH2PO4 
          High purity dH2O, pH 7.4 
 
PBS-T 
 1X PBS 
 0.1%    Tween-20 
 
Kinase Buffer, 1X 
 25 mM  Tris-HCl, pH 7.5 
 5 mM  Beta-glycerophosphate 
 2 mM  Dithiothreitol 
 0.1 mM Na3VO4 
 10 mM  MgCl2 
 
Src Kinase Dilution Buffer, 1X 
 100 mM HEPES 
 2 mM  Dithiothreitol 
 0.2 mM activated Na3VO4 
 0.02%  BSA 
 3 Unit/ml Src Kinase 
 
RIPA Lysis Buffer, 1X      
 50 mM  Tris-HCl, pH 7.4 
 150mM  NaCl   
 1%  Nonidet P-40  
 1 mM  activated Na3VO4  
 1 mM  PMSF   
 5 mM  EDTA, pH 8.0 
 1 µg/ml Aprotinin 
 1 µg/ml Leupeptin 
        Filter sterilized 
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Protease and phosphatase inhibitors were added freshly before cell lysis. 
 
 
Laemmli Buffer, 2X 
  0.5 M   Tris-HCl, pH 6.8 
 5%  β-Mercaptoethanol 
 0.1%  Bromophenol Blue 
 20%  Glycerol 
 4%  SDS 
  
Towbin Transfer Buffer, 1X 
 25 mM  Tris-HCl, pH 8.3 
 192 mM  Glycine  
 20%   Methanol 
              High purity dH2O 
 
Tris Buffered Saline (TBS) Buffer, 10X 
 1M  Tris-HCl, pH 7.4 
 1.5M  NaCl 
 
TBS-T Buffer 
 1X TBS 
 0.1%    Tween-20 
 
SDS Electrophoresis Buffer, 10X 
 0.25 M  Tris 
1.92 M  Glycine 
1%   SDS 
High purity dH2O, pH 8.3 to 1000 ml 
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Solutions for Casting One 10% Separating and One Stacking Gel 
      Separating gel, 10%  Stacking gel  
 H2O       1.9 ml        1.4 ml 
 30% Acrylamide/Bis Solution   1.7 ml        0.33 ml 
 1.5M Tris-HCl (pH 8.8)    1.3 ml           - 
 1M Tris-HCl (pH 6.8)       -       0.25 ml 
 10% SDS     0.05 ml      0.02 ml 
 10% Ammonium Persulfate   0.05 ml      0.02 ml 
 TEMED               0.002 ml     0.002 ml  
 
Milk Blocking Solution 
 5% w/v nonfat dry milk dissolved in TBS-T buffer 
 
Ponceau S Staining Solution 
 0.5g of Ponceau S was dissolved in 1 ml of glacial acetic acid and the volume was 
adjusted to 100 ml with H2O. 
 
TMB Substrate Solution 
 One tablet of the HRP substrate TMB was dissolved in 100 µl of DMSO and added per 
10 ml of phosphate citrate buffer with Sodium Perborate.  
  
Nicoletti buffer (Propidium Iodide Staining) 
 0.1%  Sodium Citrate, pH 7.4 
 0.1%  Triton X-100 
 50 µg/ml Propidium Iodide 
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5.2 Methods 
 
5.2.1 Cell biological methods 
   
5.2.1.1  Cell culture techniques 
 
The cells were cultivated under aseptic conditions in 75-cm2 tissue culture flasks. All tissue 
culture flasks have caps with filters which allow gaseous exchange, allowing maintenance of 
correct pH (which is monitored by the colour of the phenol red present in the medium) and the 
right percentage of CO2 (5%). The optimal atmosphere conditions are allowed by CO2 incubator, 
which automatically control temperature and pCO2; it operates with a try of water on the base in 
an attempt to maintain more than 98% relative humidity. Temperature of the incubator was set at 
37°C and regularly controlled.  
Human highly metastatic pancreatic carcinoma cells L3.6pl were maintained as monolayer 
cultures in Dulbecco´s Modified Eagle Medium (D-MEM) supplemented with 10% FBS, L-
glutamine, sodium pyruvate, nonessential amino acids, vitamins, and penicillin-streptomycin 
mixture. The cultures were tested and found to be free of Mycoplasma and the following 
pathogenic murine viruses: reovirus type 3, pneumonia virus, K virus, Theiler’s encephalitis 
virus, Sendai virus, minute virus, mouse adenovirus, mouse hepatitis virus, lymphocytic 
choriomeningitis virus, ectromelia virus, and lactate dehydrogenase virus (assayed by M. A. 
Bioproducts, Walkersville, MD). The cultures were maintained for no longer than 12 weeks after 
recovery from frozen stocks. 
Human umbilical vein endothelial cells were grown in Falcon "surface-modified", polystyrene 
flasks with complete Endothelial Cell Growth Medium. After adding the “SupplementMix” the 
concentrations of growth factors in the complete medium were as follows: 
Fetal Calf Serum  2% 
ECGS/H   0.4% 
Epidermal Growth Factor  0.1 ng/ml 
Hydrocortison   1 µg/ml 
Basic Fibroblast Factor  1 ng/ml 
The cells cultured in Endothelial Cell Growth Medium were checked regarding their 
morphology, the adherence rate and the population doubling time. All experiments were 
performed with cells passaged three to seven times after their receipt from the supplier.  
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Growth medium was changed every 2-3 days. The cells were split into the new culture flasks 
when they reached 80-90% confluence. Old medium was removed and the cells were washed 
twice with sterile PBS buffer. Then 1 ml of trypsin-EDTA solution was added, the culture flask 
was incubated at 37°C and observed under the microscope until cells detached from the surface 
of the flask. Then 10 ml of complete fresh medium was added to inactivate the activity of 
trypsin. Cells were centrifuged (except for HUVE cells) at 1000 g for 4 min at room temperature. 
Medium was discarded and the cells were resuspended in fresh growth medium. 
       
5.2.1.2  Cell quantification and evaluation of viability    
 
An efficient way of counting cells and at the same time the evaluation of percentage of viable 
cells is the technique of “dye exclusion”. This test is based on the concept that viable cells do not 
take up some dyes, whereas dead cells are permeable to these dyes. Trypan blue is the most 
commonly used dye. In the cell culture some misleading situations such as recent trypsinization 
and freezing and thawing in presence of dymethylsulphoxide (DMSO) may lead to membrane 
leakeness. From each suspension cells an aliquot of 10 µl was harvested, mixed with 10 µl of 
tryplan blue and counted on a counting chamber under the microscope. The mean of at least 
three counts of viable cells (not stained with trypan blue)/quadrant was considered and 
multiplied to the magnitude (104) and the dilution factor. 
 
5.2.1.3  Cell stimulation with different factors     
 
For cytokine induction HUVE cells were maintained overnight (16 h) in the appropriate medium 
with 0.5% fetal calf serum (reduced medium) in order to synchronize the cell culture. The factors 
were diluted to the stock concentrations recommended by the manufacture in BSA 0.1% in 
sterile PBS. For further use the cytokines were diluted directly in the cell culture reduced 
medium at the indicated concentrations for desired period of time. 
 
5.2.1.4  Storage of cells        
 
In order to minimize the cellular injury induced by freezing and thawing procedures 
(intracellular ice crystals and osmotic effects), a cryoprotective agent DMSO was added. A 
variable number of L3.6pl cells (between 1-2 x 106) was spin down and resuspended in 10% 
DMSO solution (DMSO diluted in FBS). Afterwards, 1 ml aliquots of cell suspension were 
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dispensed into criotubes (1.8 ml). The tubes were placed into wells of a brass block pre-cooled at 
4°C. The block was then kept at –70°C for 24 h after which the ampoules of cells were 
transferred to liquid nitrogen for long-term storage.  
For revival of cells a frozen ampoule was thawed rapidly in a 37°C water bath, disinfected and 
the content was put in a cell culture flask with pre-warmed medium. After 6 hours the medium 
was discarded and fresh pre-warmed medium was added. 
 
5.2.1.5  Detection of viable cells       
 
Measurement of cell viability forms the basis for in vitro assays of a cell population’s response 
to external factors. The reduction of tetrazolium salts is now widely accepted as a reliable way to 
examine cell proliferation. The yellow tetrazolium MTT (3-[4, 5-dimethylthiazolyl-2]-2, 5-
diphenyltetrazolium bromide) is reduced by metabolically active cells, in part by the action of 
dehydrogenase enzymes, to generate reducing equivalents such as NADH and NADPH. The 
resulting intracellular purple formazan can be solubilized and quantified by spectrophotometric 
means. 
For an assessment of AZM475271 activity directed against cultured L3.6pl and HUVE cells, we 
used an in vitro TACS MTT Cell Proliferation and Viability Assay Kit. Cells were removed 
from subconfluent cultures by treatment with trypsin-EDTA. Trypsinization was stopped with 
complete medium. Cell suspension was harvested by centrifugation (400 g for 4 min at room 
temperature), 15 × 103 cells/well were plated in 96-well plates in complete medium (amount of 
the cells was determined by trypan blue method, 5.2.1.2). After 24 hours of attachment, cells 
were treated with AZM475271 (1 – 25 µmol/L), and the plates were incubated for another 72 
hours (37°C, 5%CO2). Cells were washed with PBS; the MTT Reagent was added according to 
the manufacturer’s recommendations to each well, including controls. The plates were returned 
to cell culture incubator for 2 to 4 hours, and when the purple precipitate was clearly visible 
under the microscope the MTT Detergent was added to all wells, including controls. The plates 
were left with cover in the dark for 2 to 4 hours at room temperature. The absorbance in each 
well (OD, optical density) was measured at 570 nm in a microplate spectrophotometer. The IC50 
(the concentration of AZM475271 at which 50% of cells were viable compared to cells grown in 
the absence of Src kinase inhibitor) was calculated using the following formula: 
IC50 = OD of the cells treated / OD of untreated cells x 100% 
All experiments were replicated three times. 
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5.2.1.6  Inhibition of growth factor-mediated endothelial proliferation   
 
HUVEC proliferation in the presence and absence of growth factors was evaluated using 3-(4, 5-
dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) incorporation. Briefly, HUVE 
cells were plated in 96-well plates (15 × 103 cells/well) in reduced medium and dosed with 
AZM475271 ± VEGF165 or EGF (both growth factors at concentration 25 ng/ml were taken). 
The cultures were incubated for 72 hours (37°C, 5%CO2) and then assayed for the incorporation 
of MTT using the microplate spectrophotometer, as described above (5.2.1.5). The IC50 dose of 
AZM475271 was assumed as the dose which inhibited 50% of HUVE cell proliferation. 
All experiments were replicated at least three times. 
 
5.2.1.7  Chemotaxis assay        
 
Chemotaxis experiments were performed using BD BioCoat™ Matrigel invasion chambers. The 
apparatus consists of a BD Falcon TC companion plate with Falcon cell culture inserts 
containing an 8 µm pore size PET membrane with a thin layer of MATRIGEL Basement 
Membrane Matrix. The Matrigel Matrix serves as a reconstituted basement membrane in vitro. 
The layer occludes the pores of the membrane, blocking non-invasive cells from migration 
through the membrane. In contrast, invasive cells (malignant and non-malignant) are able to 
detach themselves from and invade through the Matrigel Matrix and the 8 µm membrane pores. 
The membrane may be processed for light and electron microscopy and can be easily removed 
after staining.  
HUVECs (105 cells/well) resuspended in reduced medium were seeded into the upper well of the 
chamber system on a human fibronectin-coated polyethylene terephthalate membrane with 8 µm 
pores. Human recombinant VEGF165 diluted in the cell culture reduced medium was added as a 
chemo-attractant into the lower well at 20 ng/ml. Inhibition of VEGF-induced chemotaxis was 
assessed after including AZM475271 at relevant doses to the upper compartment of the chamber. 
The cells were allowed to migrate for 4 hours at 37°C, after which the filter was fixed with cold 
methanol and stained with haematoxylin. The non-invading cells were removed from the upper 
surface of the membrane by “scrubbing” with a cotton swab, and the number of migrated cells 
was counted in 5 random 0.159-mm2 fields at x100 magnification. 
The average of triplicate inserts from three representative experiments was obtained.   
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5.2.2 Biochemical methods         
 
5.2.2.1  Inhibition of protease/phosphatase activity      
A commercially available cocktail of protease/phosphotase inhibitors (final concentrations: 0.02 
mg/ml pancreas extract, 5 µg/ml pronase, 0.5 µg/ml thermolysin, 3 µg/ml chymotrypsin and 0.33 
mg/ml papain) was prepared just before use and employed when needed. 
 
5.2.2.2  Preparation of cellular extracts using RIPA buffer  
  
During RIPA lysis intracellular and membrane proteins are solubilized due to the presence of 
detergent and high salt concentration in the lysis buffer. Nonsolubilized proteins are precipitated 
by centrifugation. Protease inhibitor cocktail is included in the lysis buffer to prevent proteolysis, 
phosphotase inhibitor cocktail - to maintain the phopsphorylation status of phosphoproteins, 
EDTA - to chelate divalent ions that are essential for metalloproteases. 
Trypsinized HUVE cells (5.2.1.1) were washed twice with ice cold PBS, collected by 
centrifugation at 400 g for 4 min at 4°C. Cells were than resuspended in ice cold RIPA buffer 
supplemented with the cocktail of protease/phosphotase inhibitors to a final concentration of 
about 107-108 cells/ml. Cells were incubated on ice for 10 min and centrifuged at 14000 g at 4°C 
for 10 min. The supernatant containing total cellular proteins was collected and stored at –20°C. 
Total protein concentration in the supernatant was determined as described below (5.2.2.3). 
 
5.2.2.3  Determination of protein concentration     
 
The BCA™ Protein Assay Reagent Kit was used to measure protein concentration in cellular 
lysates.  The BCA method combines the well-known reduction of Cu+2 to Cu+1 by protein in an 
alkaline medium and selective colorimetric detection of the cuprous cation (Cu+1) with a reagent 
containing bicinchoninic acid (BCA). The purple-colored reaction product of this assay is 
formed by the chelation of two molecules of BCA with one cuprous cation. This complex has a 
strong absorbance at 562 nm that is nearly linear with increasing protein concentrations. 
Five µl of protein lysates were diluted in 45 µl of water and plated in 96-well plate. Protein 
standards for calibration were prepared by diluting 0, 5, 15 and 30 µg of bovine serum albumin 
(BSA) from 2 mg/ml stock solution in water to the final volume of 100 µl. Working BCA 
reagent was prepared freshly by mixing reagent A (containing bicinchoninic acid, sodium 
carbonate, sodium bicarbonate and sodium tartrate in 0.1M sodium hydroxide) and reagent B 
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(containing 4% cupric sulfate) from the kit at the ratio of 1:50 vol./vol.. Fifty µl/well of working 
BCA reagent was added to protein samples. Plates were placed in 60°C for 30 minutes, and then 
were allowed to cool down at room temperature for about 10 minutes. The absorbance was 
measured at or about 562 nm on the microplate spectrophotometer. A standard curve was 
prepared by plotting the average Blank-corrected 562 nm measurement for each BSA standard 
vs. its concentration in µg/ml. The standard curve was used to determine the protein 
concentration of each unknown sample. 
 
5.2.2.4  Immunoprecipitation of proteins from cellular lysates 
 
In this approach, specific antibody is added to the cellular lysate to bind protein of interest. 
Antibody-protein complexes are then precipitated using solid-phase matrix. Bacterial proteins A 
and G which have specific binding sites for Fc-parts of antibodies, covalently coupled to cross-
linked agarose, are usually used as solid-phase matrix to precipitate protein-antibody complexes. 
Cellular lysates containing 0.5-1 mg of total protein were mixed with about 1 µg of antibody in 
pre-chilled 1.5 ml tubes on ice. Volumes of the mixture were adjusted to 200-300 µl to obtain 
equal protein concentrations in each sample. Tubes were incubated for 4 hours at 4°C with 
constant rotation. 20-25 µl of Protein A or G coupled agarose was added to each sample and 
tubes were incubated for additional 4 hours at 4°C with constant rotation. Following incubation 
with Protein A or G agarose, immuno-complexes were pelleted by centrifugation at 4500 g at 
4°C for 1 minute and washed 3 times with ice-cold RIPA lysis buffer and one time with ice-cold 
1X kinase buffer. Each time complexes were collected by centrifugation at 4500 g at 4°C for 1 
minute. Five-10 µl of the kinase buffer used for the last wash were left above the agarose pellet. 
Ten µl of 2X Laemmli loading buffer were added to the samples and proteins were denatured by 
heating to 95°C for 5 minutes. Samples were cooled down on ice and analyzed immediately or 
frozen at –80°C for later analyses. Protein A or G agarose was pelleted by centrifugation at 
14000 g at 4°C for 30 minutes and supernatants, containing immunoprecipitated proteins were 
analyzed by SDS-PAGE electrophoresis (5.2.2.5). 
 
5.2.2.5  SDS-Polyacrylamidgelelectrophoresis PAGE     
   
In this approach proteins in the mixture are denatured by heating in the presence of 2-
mercaptoethanol and SDS. Denatured polypeptides bind SDS and become negatively charged. 
The amount of bound SDS is almost always proportional to the molecular weight of a 
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polypeptide, and is independent of its sequence. Therefore proteins and protein subunits are 
separated according to their size during migration through the pores in the gel matrix in response 
to an electrical field.  
Protein samples for electrophoresis were prepared by dissolving a mixture of proteins in SDS-
PAGE loading buffer and heating up the samples at 95°C for 5 minutes (5.2.2.4). 
Separation gels with the following dimensions were used: thickness 1.0 mm, length 7.3 cm and 
width 8.3 cm. One µl TEMED per 1 ml of gel mix was used for the catalysis of the 
polymerization reaction, which was initiated by adding APS to a final concentration of 0.1%. 
The stacking gel was composed similar to the running gel, only Tris-HCl with pH 6.8 was used 
and the acrylamid had a final concentration of 3%. Proteins were separated at 250V and 30 mA 
until the dye front has left the separation gel. 
 
5.2.2.6  Transfer of proteins to PVDF membrane     
 
Proteins separated by SDS-PAGE were transfered to a PVDF membrane Hybond P. The transfer 
was done in a semi-dry TRANS-BLOT SD cell (Fig. 5.3) applying 25V and 100mA for 90 
minutes. In semi-dry blotting the electrodes are placed directly in contact with the 
gel/nitrocellulose membrane sandwich to provide a fast, efficient transfer. Because of this direct 
contact there is a minimum of transfer buffer required for this process. 
PVDF membrane was soaked in methanol for a few minutes and then transferred to a container 
with Towbin transfer buffer. Gel and attached PVDF membrane were sandwiched between two 
pieces of Whatman paper and soaked in the transfer buffer. 
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Figure 5.3 An exploded view of the Trans-Blot SD cell: 1, safety lid; 2, cathode assembly with 
latches; 3, filter paper; 4, gel; 5, membrane; 6, filter paper; 7, spring-loaded anode platform, 
mounted on four guide posts; 8, power cables; 9, base. 
 
 The prestained protein ladder served as a control for the transfer. 
 
5.2.2.7  Ponceau S staining of proteins on PVDF membrane   
 
Staining with Ponceau S was used to provide visiual evidence that electrophoretic transfer of 
proteins has taken place. Ponceau S is a negative stain which binds to the positively charged 
amino groups of the protein.  
PVDF membrane was incubated for 5-10 seconds in Ponceau S staining solution and then 
washed with water until the protein bands became visible.  
 
5.2.2.8  Analysis of proteins on PVDF membrane by immunoblotting   
 
In this method, specific antibodies are used to identify proteins transferred to PVDF membrane. 
First, membrane is immersed in blocking buffer to fill all protein binding sites with non-reactive 
protein. Then membrane is incubated in a solution containing antibody directed against the 
antigen(s) in the protein to be detected. Primary antibody bound to the protein of interest are 
recognized by secondary antobody conjugated with horseradish peroxidase (HRP). The complex 
containing the antigen, primary antibody and secondary antibody-HRP conjugate is detected by 
chem luminescent visualization using ECL detection system. 
PVDF membranes were blocked in the blocking solution either for 1-3 hours at room 
temperature or overnight at 4°C. After blocking, membranes were then washed once for 15 
minutes and twice for 5 minutes in TBS-T buffer with agitation. After the washes membranes 
were incubated with antibodies appropriately diluted in 5% BSA in TBS-T overnight at 4°C with 
agitation. After incubation with primary antibodies, membranes were washed again as described 
above, then transferred to the containers with secondary antibody-HRP conjugates in 5% BSA in 
TBS-T and incubated for 1 hour at room temperature shaking gently. Membranes were then 
rinsed twice and washed with agitation twice for 15 minutes, twice for 10 minutes, and twice for 
5 minutes. For detection, membranes were incubated in a mixture of ECL Western Blotting 
detection reagents for 2 minutes. Remaining drops of ECL buffer were removed and membranes 
were placed into a transparent folder. Hyperfilm ECL was then exposed for an appropriate time 
and developed with an AGFA developing system. 
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5.2.2.9  Stripping and re-probing of western blot 
 
PVDF membranes were stripped and re-probed using Restore™ Western Blot Stripping Buffer.  
Twenty ml of Restore™ Western Blot Stripping Buffer were warmed to room temperature. 
Membranes were placed in the buffer to be stripped and incubated for 15 minutes at room 
temperature. After incubation, the blots were removed from the buffer and washed 3 times for 15 
min in TBS-T. After determining that the membranes were properly stripped, next 
immunoprobing experiments were performed. 
 
5.2.3 Determination of apoptotic cells by FACS analysis via propidium iodide staining 
 
Propidium Iodide (PI) binds to double-stranded DNA, but it can only cross the plasma membrane 
of non-viable cells. For analysis by flow cytometry, the PI staining can be monitored in the FL2 
channel.  
HUVE cells were plated into T75 flasks and treated with different concentrations of 
AZM475271 (0 – 25 µM). After 12 hours, cells were collected and suspended in a Nicoletti 
buffer and incubated for 15 min protected from light at room temperature. The supernatant was 
discarded by centrifugation of cell suspension at 1300 g for 4 min. After 2 washing steps with 
PBS, cells were finally resuspended in sterile PBS and the DNA content present in the resulting 
nuclei was determined on a fluorescence-activated cell sorter (FACS). Signal height, area, and 
width were recorded for the PI channel. Data analysis was done using the WinMDI 2.8 software. 
Sub-G0/G1 was then quantified and used as an estimate of the amount of the cells undergoing 
apoptosis. The cellular debris was excluded from the analysis. Experiments were repeated three 
times.  
 
5.2.4 Enzyme-linked immunoassays       
 
5.2.4.1  Determination of human vascular endothelial growth factor concentrations 
in cell culture supernates   
 
This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal 
antibody specific for VEGF has been pre-coated onto a microplate. Standards and samples are 
pipetted into the wells and any VEGF present is bound by the immobilized antibody. After 
  Chapter 5. Materials and methods  
 - 54 - 
washing away any unbound substances, an enzyme-linked polyclonal antibody specific for 
VEGF is added to the wells. Following a wash to remove any unbound antibody-enzyme 
reagent, a substrate solution is added to the wells and color develops in proportion to the amount 
of VEGF bound in the initial step. The color development is stopped and the intensity of the 
color is measured. 
The level of VEGF was measured in cell culture supernates collected on day 0, 2, and 4 from 
L3.6pl or HUVE cells following treatment with Src kinase inhibitor AZM475271 at different 
concentrations (0.1, 1 µM). The assay was performed according to the manufacturer’s 
recommendations. Absorbance at 450 nm was measured and corrected using the 540-nm reading 
on the microplate reader. VEGF content was calculated according to the parameter of the 
calibration curve. Calibration curves with a correlation coefficient at least 0.998 were used. All 
experiments were replicated three times.  
 
5.2.4.2  In vitro Src kinase inhibition test      
 
A poly (Glu, Tyr) 4:1 random copolymer was used as the tyrosine-containing substrate. This is 
stored as a 10 mg/ml stock solution in PBS at 20°C and diluted 1:200 with PBS to coat 96-well 
plates (100 µl/well). Substrate was plated the day before the assay, and the plates were covered 
with adhesive seals and stored overnight at 4°C. On the day of the assay, the substrate solution 
was discarded, and the plates were then incubated with 120 µl/well of 5% BSA in PBS for 10 
minutes. The plates were then washed once with PBS-T and incubated with 50 mmol/L HEPES 
(pH 7.4) at 100 µl/well until the next stage. Confluent HUVE or L3.6pl cells were treated with 
different concentrations of AZM475271 or PP2. After 12 hours cells were washed and lysed in 1 
ml of ice-cold RIPA lysis buffer. Lysates were clarified by centrifugation at 14000 g for 10 
minutes and active src was then precipitated using 15µg of v-src (Ab-1) monoclonal antibody 
pre-adsorbed to 50µl of protein G-sepharose. The immune complexes containing precipitated src 
were washed 3 times with ice-cold RIPA lysis buffer, one time with ice-cold 1X kinase buffer 
and used in kinase reaction as an active src kinase. Solutions of 80 µmol/L ATP in 80 mmol/L 
MgCl2 and 80 mmol/L MgCl2 alone (negative controls) were prepared. The HEPES was 
discarded from the substrate plates and the following additions were now made in this order: 25 
µl/well ATP/MgCl2 or MgCl2 alone; 50 µl/well beads to start the reaction. The reaction time 
allowed was 30 minutes at room temperature on a plate shaker. The assay was stopped by 
washing the plates four times with PBS-T (150 µl/well). Detection of the resultant tyrosine 
phosphorylation was facilitated by the addition of an anti–phospho-tyrosine monoclonal antibody 
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conjugated to HRP (diluted 1:5000 in PBS-T + 0.5% BSA + 0.1 mmol/L sodium orthovanadate), 
added at 100 µl/well and incubated for 1 hour. The plates were again washed (six times). TMB 
substrate solution (100 µl/well) was added. After 5 minutes of color development, the reaction 
was stopped by the addition of 50 µl/well 0.8 mol/L H2SO4. Control and blank wells were 
included on all plates containing compound diluent and MgCl2 solution with and without ATP, 
respectively, to determine the dynamic range of the assay. The in vitro VEGF-R2 kinase 
inhibition assay determines the ability of AZM475271 to inhibit VEGF-R2 kinase activity and 
has been used as a selectivity screen. The method was performed as reported previously (Lu et 
al., 2003). 
 
5.2.5 In vitro study of angiogenesis       
 
5.2.5.1  Aortic ring assay 
 
Angiogenesis was studied by culturing aortic explants in three-dimentional matrix gels according 
to the procedure of Nikosia and Ottineri (Nikosia et al., 1990). Thoracic aortas were removed 
from 6- to 8- week-old male ACI rats and immediately transferred to a culture dish containing 
cold serum-free Dulbecco´s Minimal Essential Medium. The peri-aortic tissue was carefully 
removed with fine microdissecting forceps and scissors, paying special attention not to damage 
the aortic wall. One mm long aortic slices (approximately 15 per one aorta) were sectioned and 
extensively rinsed in 5 consecutive washing steps with D-MEM. Ring-shaped explants of the 
aorta were then embedded on Matrigel-coated 24-well plates. HEPES-buffered D-MEM 
containing AZM475271 in different concentrations was added and the plates were incubated at 
37°C, 5% CO2, for 4 days. Fresh medium with respective additives was reintroduced into the 
cultures on day 2. The rings were examined by phase contrast microscopy with a Zeiss Axiotech 
Vario microscope at ×10 magnification. An estimation of the length of the capillary was 
performed by measuring the distance from the aortic explant to the approximate mean point of 
capillary. The length of the capillary was measured using AxioVision software. 
 
5.2.5.2  Spheroid angiogenesis assay 
 
To evaluate the anti-angiogenic properties of AZM475271, we used an in vitro angiogenesis 
assay as described in detail, previously (Korff et al., 1998). 103 HUVECs (passage 4 to 6) per 
spheroid were plated into a non-adhesive, round bottom 96-well plate. After 24 hours, the 
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spheroids were harvested and half the spheroids of a 96-well plate (approximately 48 spheroids) 
were embedded in 1 ml of a collagen matrix and transferred into a 24-well plate. For the next 24 
hours we incubated the embedded spheroids with the allocated treatment and thereafter, the 
spheroids were fixed in a 4% formalin solution to prepare them for the subsequent analysis. 
Spheroid sprouting was stimulated with human recombinant VEGF-A165 (25 ng/ml) in the 
presence or absence of AZM475271. The pictures of the spheroids were taken under trans-
illumination using an Achroplan objective (n.a. = 0.45) providing a 20-fold magnification.  
 
5.2.6 Orthotopic xenograft pancreatic tumor model     
 
5.2.6.1  Tumor cell implantation       
 
For in vivo injection, L3.6pl human pancreatic carcinoma cells were harvested from culture 
flasks by a treatment with trypsin-EDTA and resuspended in sterile ice-cold PBS. Only single-
cell suspensions of >90% viability (trypan blue exclusion) were used for injection. Male nude 
mice were anesthetized with ketavet (100 mg/kg mouse body weight) and xylazin (5 mg/kg 
mouse body weight) followed premedication with atropine sulfate. A small left abdominal flank 
incision was made and the spleen exteriorized (Fig. 5.4a). L3.6pl tumor cells (1x106 in 40µl 
PBS) were injected subcapsularly in a region of the pancreas just beneath the spleen. We used a 
30-gauge needle, a 1 ml disposable syringe, and a calibrated pushbutton-controlled dispensing 
device to inject the tumor cell suspension (Fig. 5.4b). A successful subcapsular intrapancreatic 
injection of tumor cells was identified by the appearance of a fluid bleb without intraperitoneal 
leakage (Fig. 5.4c). To prevent such leakage, a cotton swab was held for 1 min over the site of 
injection. One layer of the abdominal wound was closed by suture.  
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Figure 5.4 Orthotopic tumor cell injection 
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The animals tolerated the surgical procedure well, and no anesthesia-related deaths occurred. 
 
5.2.6.2  Treatment of established tumors growing in the pancreas of nude mice 
 
Seven days after implantation of tumor cells, mice were randomly assigned to one of the 
following groups of 5-9 mice each: 
1) Daily intragastral administration of Src tyrosine kinase inhibitor  AZM475271 at 
a dose of 25 mg/kg mouse body weight;  
2) Daily intragastral vehicle solution for AZM475271 (Tween 20 diluted 1:100 in 
NaCl).  
 
5.2.6.3  In vivo evaluation of plasma concentration levels of AZM475271  
 
Healthy nude mice were treated with a single dose of 50 mg/kg AZM475271 by oral 
administration. The plasma concentration of AZM475271 was measured by mass spectrometry 
2, 6, and 24 hours after oral feeding of the compound.  
 
5.2.6.4  Monitoring of mouse body weight and tumor volume   
 
Starting 3 days after the initiation of therapy with AZM475271, the measurement of tumor 
volume (by transcutaneous palpation) and mouse body weight was performed.  
 
5.2.6.5  Necropsy procedure and histopathological studies   
 
The animals were sacrificed 32 days after the initiation of treatment, when > 50% of the control 
animals had become moribund. Primary pancreatic tumor size, liver and lymph node metastasis, 
and local peritoneal carcinosis were assessed. All palpable or visible masses in the pancreas were 
considered pancreatic tumors and the presence of tumor was later confirmed by Haematoxylin 
and Eosin (H&E) staining. Excised pancreatic tumors were weighed. The tumor volume was 
then calculated using the formula V = π/6 (a × b × c), where a, b and c represent the length, width, 
and height of the mass. Microscopically, tumor nodules ≥1 mm in diameter were counted on the 
entire liver surface. Where visible liver metastases were evident, the tissue was processed for 
H&E staining to confirm the macroscopic observations. Furthermore, macroscopically-enlarged 
regional lymph nodes (celiac and para-aortic) were excised and H&E staining performed to 
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confirm the presence of metastases. Tumor lesions were harvested, some were fixed in 10% 
buffered formalin and embedded in paraffin, and some were embedded in optimum cutting 
temperature (OCT) compound, snap-frozen in liquid nitrogen, and stored at -70°C.  
 
5.2.7 Immunohistochemical analyses       
 
5.2.7.1  Immunohistochemistry of paraffin embedded tissues   
 
5.2.7.1.1 Haematoxylin and Eosin staining     
 
Staining of the nucleus of the cells was done with haematoxylin; eosin was used for the 
cytoplasm staining. Samples were deparaffinized by incubation in xylene for 20 min, 2 minutes 
in 100%, one minute in 96 %, one minute in 75% ethanol and finally washed in distilled water. 
The samples were then rinsed in haematoxylin for one minute, washed in distilled water and 
incubated with eosin for 2 minutes. After washing the slides were mounted with Mayer gel. 
 
5.2.7.1.2 Staining for Ki-67 antigen (The assessment of cell proliferation) 
 
Evaluation of cell proliferation was performed using Ki-67-specific polyclonal rabbit anti-human 
antibody. Tissues were embedded in paraffin and 4–6 µm sections were prepared and mounted 
on positively-charged superfrost slides. Sections were dried overnight, deparaffinized in xylene 
and incubated in 100%, 95% and 80% ethanol (v/v in distilled water), before rehydrating in PBS. 
Ki-67 antigen retrieval was achieved by microwaving tissue sections for 15 minutes at 750W. 
After cooling down, the slides were rinsed with PBS, and nonspecific binding sites were blocked 
with 5% bovine serum albumin (BSA) in PBS. After another washing step with PBS, the 
primary antibody (1:75, a polyclonal rabbit anti-human antibody against Ki-67) was applied, and 
the slides were incubated for 2 hours at room temperature. The samples were then incubated with 
biotinylated goat anti-rabbit secondary antibody (1:200) for 1 hour at room temperature, 
followed by incubation with an avidin-biotinylated horseradish peroxidase (HRP) complex from 
an ABC kit. Sections were examined microscopically and the average number of cells staining 
positively for Ki-67 per high-power field (0.159 mm2) was counted at x100 magnification.  
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5.2.7.2  Immunohistochemistry of snap-frozen tissues    
 
5.2.7.2.1 Terminal deoxynucleotidyl transferase–mediated nick end labeling  
(TUNEL) staining    
 
Terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) staining was 
performed using a commercially available apoptosis detection kit (DeadEnd™ Fluorometric 
TUNEL System). In many cell types, apoptosis is characterized by the generation of DNA 
fragments through the action of endogenous endonucleases. The DNA of apoptotic cells is 
cleaved into multimers of 180–200bp fragments, corresponding to the oligonucleosomal size. 
Therefore, the DNA of apoptotic cells typically migrates as a ladder of 180–200bp multimers on 
an agarose gel. The generation of single strand breaks also has been reported. The DeadEnd™ 
Fluorometric TUNEL System measures the fragmented DNA of apoptotic cells by catalytically 
incorporating fluorescein-12-dUTP(a) at 3´-OH DNA ends using the enzyme Terminal 
Deoxynucleotidyl Transferase (TdT). TdT forms a polymeric tail using the principle of the 
TUNEL (TdT-mediated dUTP Nick-End Labeling) assay. The fluorescein-12-dUTP-labeled 
DNA can then either be visualized directly by fluorescence microscopy or quantitated by flow 
cytometry.  
Tissue sections (8-10 µm thick) were fixed by immersing slides in freshly prepared 4% 
methanol-free formaldehyde solution in PBS (pH 7.4) in a Coplin jar for 25 minutes at 4°C and 
washed twice by immersing in fresh PBS for 5 minutes at room temperature. Then cells were 
premeabilized by immersing the slides in 0.2% Triton X-100 solution in PBS for 5 minutes and 
then rinsed twice in PBS for 5 minutes. After removing excess liquid by tapping, slides were 
covered with 100µl of equlibration buffer and equilibrated at room temperature for 10 minutes. 
Then, a sufficient TdT incubation buffer for all experimental and optional positive control 
reactions was prepared according to manufacture protocol. 50µl of TdT incubation buffer were 
added, slides were covered with plastic coverslips to ensure even distribution of the reagent and 
incubated at 37°C for 60 minutes inside the humidified chamber covered with aluminium foil to 
protect from direct light. After the incubation plastic coverslips were removed and reaction was 
terminated by immersing the slides in 2X SSC in a Coplin jar for 15 minutes at room 
temperature. Samples were washed twice by immersing the slides in PBS for 5 minutes at room 
temperature to remove unincorporated fluorescein-12-dUTP. Slides were mounted using glass 
coverslips and DEPEX gel. Samples were immediately analysed under a fluorescence 
microscope using a standard fluorescent filter set to view the green fluorescence of fluorescein at 
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520 ± 20nm. Results were expressed as the average of apoptotic cells in 10 random fields at x40 
magnification. 
 
5.2.7.2.2 Staining for CD31       
 
Frozen tissue sections (8-10 µm thick) were fixed with cold acetone for 5 min, acetone and 
chloroform (1:1, v/v) for 5 min, and acetone for 5 min, then washed in PBS. Endogenous 
peroxidase was blocked by incubation of slides in 3% H2O2 diluted in methanol for 5 min and 
3x3 min washed in PBS. Non-specific binding sites were blocked for 20 min with 5% horse 
serum and 1% goat serum in PBS. After the incubation, primary antibodies dissolved in 1% 
blocking buffer were applied and incubated overnight at 4°C: CD-31, monoclonal rat anti-mouse 
(1:200) which reacts to a surface antigen (CD-31) presented on all endothelial cells. Next day the 
samples were washed 3x3min in PBS and the slides were incubated for 10 min with blocking 
buffer at room temperature. Then secondary antibodies (biotinylated polyclonal rabbit anti-rat 
immunoglobulin, Ig-fraction, HRP- conjugated (1: 400) dissolved in blocking buffer were 
applied for 1 hour at room temperature. After washing 3x3 min in PBS the slides were rinsed 
with 0.2% Tween solution in PBS. Then the samples were incubated with AEC chromogen 
dissolved in H2O2 substrate, washed in distillate water and stained with haematoxylin for 1 min. 
After washing with distillate water the slides were mounted using glass cover slips and DEPEX 
gel. For the quantification of microvascular density, 10 random 0.159-mm2 fields at x100 were 
captured for each tumor using an AxioCam camera mounted on a Carl Zeiss universal 
microscope and AxioVision software. Two investigators counted the microvessels independently 
in a blinded fashion. Tissues were examined at a low power (x40), and the three x200 fields of 
highest microvessel density were identified for vessel counts. Microvessels were quantitated 
according to the method described by Bruns (Bruns et al., 2000). Clusters of stained endothelial 
cells distinct from adjacent microvessels, tumor cells, or other stromal cells were counted as one 
microvessel. The results were expressed as the highest number of microvessels identified within 
a single x200 field.  
 
5.2.7.2.3 Immunofluorescence double staining for CD31 and TUNEL   
 
Frozen tissue was used for CD31/TUNEL immunofluorescence double staining. The procedure 
used is as described previously (Baker et al., 2002).  
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TUNEL assay was done with the use of a commercial apoptosis detection kit as described above 
(5.2.7.2.1). TUNEL-positive apoptotic cells were detected by localized green fluorescence within 
the cell nuclei, and endothelial cells were identified by red fluorescence. Apoptotic endothelial 
cells were identified by yellow fluorescence within the nuclei. The total number of apoptotic 
cells was quantified in 10 randomly selected microscopic fields and expressed as the ratio of 
apoptotic endothelial cells to the total number of endothelial cells in  5–10 random 0.011-mm2 
(at x400 magnification). 
 
5.2.8 Statistical analysis  
 
Pancreatic tumor weight, mouse body weight, and quantification of Ki67, TUNEL, and CD31 
were compared using one-way ANOVA with a Student-Newman-Keuls multiple comparison 
test. The relative rates of liver and lymph node metastases within groups were compared by 
Fisher´s exact test. Survival analysis was computed by the Kaplan–Meier method and compared 
by the log-rank test (Hosmer et al., 1980). Significance was taken as p < 0.05. Results of the 
ELISA tests, proliferation assays, migration and aortic ring assays were analyzed using the 
paired Student’s t-test with p < 0.05 considered to be significant. 
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The initial goal of the work described in this thesis was to demonstrate the in vivo efficacy of the 
Src tyrosine kinase inhibitor AZM475271 in an orthotopic xenograft pancreatic tumor model. 
However, early results, which have raised questions as to the role of Src family kinases in tumor 
angiogenesis and metastasis, lead to a change the direction of the project. 
 
6.1 In vitro enzyme inhibition in HUVE and L3.6pl cells 
 
AZM475271 is a potent inhibitor of the Src tyrosine kinase activity in HUVE and L3.6pl cells. 
To demonstrate the selectivity of AZM475271, an in vitro Src inhibition ELISA was performed 
measuring the IC50 of AZM475271 necessary to prevent the ability (i.e. activity) of src kinase 
precipitated from HUVE or L3.6pl cells to phosphorylate an immobilized substrate in the 
presence of ATP. AZM475271 demonstrated a strong inhibition of Src kinase activity in HUVE 
and L3.6pl cells in a dose-dependent manner. The IC50 concentration of AZM475271 to inhibit 
the phosphorylation of Src in HUVE and L3.6pl cells was 0.1 µmol/L (Fig. 6.1, a and b, 
respectively). 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) was used 
as a positive control for Src kinase inhibition. 
 
6.2 In vitro selectivity profile of AZM475271 
A receptor tyrosine kinase inhibitor should prevent the phosphorylation of tyrosine residues on 
protein substrates following stimulation of the kinase with its specific ligand. The ability of 
AZM475271 to inhibit receptor tyrosine kinase activity (at the Michaelis constant [Km] for 
adenosine triphosphate [ATP]) was examined using an ELISA with recombinant cytoplasmic 
domains of Src non-receptor tyrosine kinases. Table 6.1 presents the kinase inhibition and 
selectivity profile of AZM475271 (data were kindly provided by AstraZeneca Pharmaceuticals). 
AZM475271 has considerable selectivity for Src versus kinase insert domain-containing receptor 
(KDR) (IC50 = 20.9 µmol/L), fms-like TK 1 (Flt-1) (IC50 > 100 µmol/L), fibroblast growth factor 
(FGF) TK, fms-like TK 4 (Flt-4), aurora kinase (AUR-3), mitogen-activated protein kinase 
(MAPK) kinase (MEK) (IC50 > 10 µmol/L), cyclin-dependent kinase-2 (CDK-2) (IC50 > 9 
µmol/L), epidermal growth factor receptor (EGF) TK (IC50 = 2.6 µmol/L). AZM475271 has 
equipotent activity against Src family members c-Yes and Lck (IC50 ≤ 0.004 µmol/L). Since the 
kinase domain is virtually identical in each member, it would be reasonable to assume that 
AZM475271 will inhibit the other family members with similar potency. The activities of Src 
kinases are normally highly regulated and AZM475271 will inhibit those that have been 
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activated. AZM475271 has poor activity against Csk, a negative regulator of Src (IC50 = 0.84 
µmol/L).  
 
 
Kinase IC50 (µmol/L) 
Fold 
selectivity 
vs. Src 
   
Src 0.0027  
KDR (kinase insert domain-containing receptor) 20.9 >7700 
Csk (negative controller of Src) 0.843 312 
Flt-1 (VEGFR1) >100 >37000 
Flt-4 (VEGFR3) >10 >3700 
FGF TK >10 >3700 
EGF TK 2.59 960 
MEK 14.03 >5000 
CDK-2 9.753 3612 
c-Yes (ubiquitous Src family member) 0.004 1.48 
Lck (T cell restricted Src family member) <0.004 <1.48 
   
 
Table 6.1 AZM475271 inhibition of Src non-receptor tyrosine kinase and selectivity profile. 
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Figure 6.1 In vitro inhibition of Src Kinase. 
ELISA was performed measuring the IC50 of AZM475271 necessary to inhibit the 
activity of src kinase, expressed in L3.6pl (A) or in HUVECs (B). 4-Amino-5-(4-
chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) was used as a positive 
control for src kinase inhibition (*, p<0.001 versus control reaction; #, p<0.001 
versus control reaction). 
 
 
 
6.3 AZM475271 inhibits tumor growth and metastasis in an orthotopic nude mouse 
model 
 
Tumors generated by orthotopic implantation of the metastatic L3.6pl cell line were used to 
evaluate the effects of AZM475271 on growth, metastasis, and angiogenesis in a nude mouse 
model. Pancreatic tumors were allowed to become established for 7 days before initiation of 
treatment. Starting 3 days after the initiation of therapy with AZM475271, the measurement of 
mouse body weight and tumor volume (by transcutaneous palpation) was performed (Fig. 6.2, a 
and b). Treatment with AZM475271 did not significantly change animal weight (at the end of 
experiment the mean animal body weight after therapy with AZM475271 was 21.6 g, compared 
to the untreated group with 22.6 g) (Fig. 6.2a). Monitoring of the tumor volume over the course 
of experiment revealed a decrease in the tumor growth progression in all animals treated with 
AZM475271 (Fig. 6.2b).  
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The animals were sacrificed 32 days after the initiation of treatment, when > 50% of the control 
animals had become moribund. At the time of necropsy, all control and treated mice had 
developed primary pancreatic tumors. Primary pancreatic tumor size, liver and lymph node 
metastasis, and local peritoneal carcinosis were assessed. Treatment with AZM475271 
significantly reduced spontaneous liver metastasis (no animals had metastases) compared with 
treatment using vehicle solution. Mice who received AZM475271 had also a significant 
reduction in the incidence of lymph node metastases (five of nine animals) (Table 6.2). Tumor 
weight for treatment group was assessed using Fisher’s Exact test. Other comparisons were made 
using the unpaired Student’s t-test. The mean tumor volume was significantly decreased (~40% 
inhibition of primary tumor growth) in all animals treated with AZM475271 (AZM475271-
treated animals, 817 mm3; control animals, 1359 mm3). Primary pancreatic tumor weight after 
AZM475271 therapy was also significantly less than that in control mice (mean weight 1.03 and 
1.45, respectively). Results are presented in the Figures 6.3a and 6.3b.  
In addition, daily intragastral administration of AZM475271 was well tolerated. 
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Figure 6.2 Monitoring of the mouse body weight (A) and L3.6pl tumor growth 
progression (B) in the orthotropic nude mouse model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.2 In vivo therapeutic efficacy of AZM475271 on primary pancreatic tumor 
growth and metastasis in the orthotopic nude mouse model 
a Incidence presented as number of animals with tumor type/ number of animals in 
group 
b Visible nodules (≥1 mm in diameter) 
c p<0.03 compared with control (Fisher’s Exact Test) 
 
 
 
Incidence of macroscopic tumorsa 
Treatment group 
Pancreas tumor Liver metastasisb Regional LN metastasis 
Saline control 5/5 3/5 5/5 
AZM475271 9/9 0/9c 5/9c 
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The photograph below shows the tumors harvested from the mice in the experiment on day 32. 
Scale bar, 1 cm.  
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Figure 6.3 In vivo inhibition of L3.6pl pancreatic tumor volume (A) and 
pancreatic tumor weight (B) in the orthotopic nude mouse model. 
L3.6pl human pancreatic cancer cells were injected into the pancreas of nude 
mice. Seven days after implantation of tumor cells, mice randomly were assigned 
to one of the following groups of 5-9 mice each: 1) daily intragastral 
administration of Src tyrosine kinase inhibitor AZM475271 at a dose of 25 mg/kg; 
2) daily intragastral vehicle solution for AZM475271. The animals were sacrificed 
32 days after the initiation of treatment. 
Box plots represent the means for each group with standard deviation of data (min 
and max) and standard error of the mean.   
 
 
6.4 In vivo evaluation of plasma concentration levels 
 
After a single oral dose (gavage) of 50 mg/kg AZM475271 to healthy nude mice, the plasma 
concentration was measured 2, 6, and 24 hours later. The plasma concentration of AZM475271 
in nude mice was 32.1 µmol/L (14.206 ng/ml), 20 µmol/L (8879 ng/ml), and 11.7 µmol/L (5187 
ng/ml) at 2, 6, and 24 hours after oral dosing with 50 mg/kg AZM475271 (Figure 6.4). 
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Figure 6.4 The plasma concentration of AZM475271 in nude mice after the single 
oral dose of 50 mg/kg AZM475271. Error bars are expressed as a 5% average of 
data. 
 
6.5 Histological analysis of tissue sections 
 
6.5.1 In vivo effect of AZM475271 on tumor cell proliferation  
 
We next analyzed the effect of AZM475271 on tumor cell proliferation in vivo by assessing the 
level of the nuclear antigen Ki-67, which is present in all phases of the cell cycle except G0. The 
mean number of Ki-67-positive tumor cells in the pancreatic tumors of control mice was 480 ± 
14. After therapy with AZM475271, the mean number of Ki-67-positive cells was 185 ± 85 
(reduced over more than 50 % compared to control mice) (Table 6.3; Fig. 6.5). These results 
indicate the in vivo antiproliferative effect of AZM475271.  
 
6.5.2 In vivo effect of AZM475271 on tumor cell apoptosis 
 
To determine the ability of AZM475271 to induce apoptosis in pancreatic carcinoma cells 
TUNEL staining was carried out. The mean number of TUNEL-positive cells was 8 ± 2 and 26 ± 
11 (p < 0.05 versus control) in control and AZM475271-treated group, respectively. Results 
showed a significant enhancement of apoptotic tumor cells in the AZM475271 therapy group 
compared to control tumors. (Table 6.3; Fig. 6.5).  
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 Positively staining cells (mean ± SD)a 
 Tumor cells 
Treatment group Ki-67 TUNEL 
Saline control 480 ± 14 8 ± 2 
AZM475271 185 ± 85b 26 ± 11c 
 
a Positive cells per field determined from measurement of 10 random 0.159-
mm2 fields at ×100 magnification. 
b p<0.001 compared with controls. 
c p<0.05 compared with controls. 
 
Table 6.3 Quantification of Ki-67- and TUNEL-positive cells in primary 
pancreatic tumors after therapy with AZM475271.  
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Figure 6.5 Immunohistochemical analyses of proliferation (Ki-67), microvessel 
density (CD31), and apoptotic cells (TUNEL) in L3.6pl pancreatic tumors 
growing in nude mice. 
A, histological sections of control and AZM475271-treated tumors; B, mean 
number of positively stained cells per field (bars represent mean ± SD), # p<0.001 
compared with controls; * p<0.05 compared with controls. 
Histopathologic evaluation of cell proliferation was performed using Ki-67 
staining. Sections were examined microscopically and the average number of cells 
staining positive for Ki-67 per high-power field (0.159 mm2) was counted at ×100 
magnification. The mean number of Ki-67 positive tumor cells after therapy with 
AZM475271 was reduced by > 50 % compared with control mice. Frozen tissues 
were used for the evaluation of microvessel density (CD31-positive structures). 
CD31 staining demonstrated no significant influence of AZM475271 on MVD of 
tumors compared with controls (p = 0.14967, the arrow delineates CD31-positive 
cells). 
In contrast, terminal deoxynucleotidyl transferase-mediated nick end labeling 
(TUNEL) staining for apoptotic cells revealed an increase in the number of cells 
undergoing apoptosis in pancreatic cancer in the AZM475271 group. The number 
of TUNEL-positive cells was counted in 10 random fields (0.159 mm2) at ×100 
magnification (bars = 100 µm).  
 
 
6.5.3 Quantification of microvessel density in primary pancreatic tumors 
 
Frozen tissues were used for the evaluation of microvessel density (CD31-positive structures). 
Clusters of stained endothelial cells distinct from adjacent microvessels, tumor cells, or other 
stromal cells were counted as one microvessel. The number of CD31-positive microvessels 
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counted per x100 field in the pancreatic tumors was lower in mice after therapy with 
AZM475271, but not significant (p = 0.14967) (Figure 6.5, the arrow delineates CD31-positive 
cells).  
 
6.5.4 In vivo effect of AZM475271 on endothelial cell survival 
 
We speculated that tumor cell apoptosis may have been due to poor perfusion after endothelial 
cell apoptosis rather then due to decreasing in microvessel density. Therefore, we developed a 
technique with which we could evaluate endothelial cell apoptosis in vivo in tissue sections. 
Endothelial cells were detected by localized red fluorescence, whereas green fluorescence was 
detected within the nuclei of apoptotic cells. Double-labeling of endothelial cells undergoing 
apoptosis resulted in localized yellow fluorescence. The total number of apoptotic cells was 
quantified in 10 randomly selected microscopic fields and expressed as the ratio of apoptotic 
endothelial cells to the total number of endothelial cells in  5–10 random 0.011-mm2 (at x400 
magnification).  
The number of endothelial cells undergoing apoptosis was significantly greater in pancreatic 
tumors from mice treated with AZM475271 compared to control tumors (24 ± 9.1 for 
AZM475271 compared with 0.7 ± 1.5 for untreated control, p = 0.01) (Fig. 6.7). Clusters of 
apoptotic tumor cells were seen surrounding apoptotic endothelial cells when treated with 
AZM475271 (Fig. 6.6, the arrows delineate TUNEL-positive endothelial cells). 
This finding suggests that the reduced tumor size that followed therapy with Src inhibitor was 
not wholly a direct consequence of inhibition of tumor cell proliferation. There was a statistically 
significant induction of endothelial cell apoptosis in the pancreatic tumor model when 
AZM475271-treated tumors and control tumors were compared, suggesting that the reduction in 
tumor growth and metastasis in the treated group was due to endothelial cell death and not to a 
direct effect on the tumor cells themselves. 
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Figure 6.6 Immunofluorescent staining of L3.6pl human pancreatic tumors from 
mice treated with AZM475271. 
Serial tissue sections were stained with the immunofluorescent endothelial cell 
marker (CD31) and the immunofluorescent apoptosis marker (TUNEL). A 
representative sample (×100 magnification) of this CD31/TUNEL fluorescent 
double-staining is shown. Fluorescent red, CD31-positive endothelial cells; 
fluorescent green, TUNEL-positive cells; fluorescent-yellow, TUNEL-positive 
endothelial cells; bar = 100 µm, the arrows delineate TUNEL-positive endothelial 
cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 Apoptosis of endothelial cells of microvessels after therapy with 
AZM475271. 
§ The total number of apoptotic cells was quantified and expressed as the ratio of 
apoptotic endothelial cells to the total number of endothelial cells in 5–10 
random 0.011-mm2 (at x400 magnification).  
Box plots represent the means for each group with standard deviation of data 
(min and max) and standard error of the mean.  
 
6.6 In vitro antiproliferative activity of AZM475271 in L3.6pl and HUVE cells 
 
Viability assays for L3.6pl and HUVE cells were performed with the TACS MTT Cell 
Proliferation and Viability Assay Kit. Treatment of HUVECs with AZM475271 at high 
concentrations (> 10 µmol/L) caused a rapid decrease in cell proliferation that could be linked to 
the ability of AZM475271 to induce HUVEC death, whereas a significant antiproliferative 
activity of AZM475271 on HUVECs could be already observed at concentrations of 2 µmol/L or 
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above (IC50 = 6 µmol/L) (Fig. 6.8). Interestingly, no significant inhibition of proliferation was 
seen on L3.6pl cells at doses up to 5 µmol/L. The antiproliferative effect of AZM475271 on 
L3.6pl was seen exclusively at very high doses (IC50 = 25 µmol/L) (Fig. 6.8). These results 
suggest that the anti-angiogenic properties of AZM475271 might predominantly be mediated 
through a direct effect on the endothelial cells rather than via inhibition of tumor cells. 
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Figure 6.8 In vitro effects of AZM475271 on tumor and endothelial cell 
proliferation. 
Viability assays for HUVE (a) and L3.6pl (b) cells with AZM475271 were 
performed with the TACS MTT Cell Proliferation and Viability Assay Kit. 
Treatment of HUVECs with AZM475271 at high concentrations (>10 µmol/L, p< 
0.0001 versus AZM475271 0 µmol/L) caused a rapid decrease in cell proliferation 
that could be linked to the ability of AZM475271 to induce HUVEC death. The 
IC50 concentration was reached at 6 µmol/L for HUVECs and at 25 µmol/L for 
L3.6pl cells, respectively. 
 
6.7 In vitro effects of AZM475271 on VEGF- and EGF- dependent endothelial cell 
proliferation 
 
The effects of exogenous VEGF or EGF on endothelial cell proliferation were analyzed using the 
TACS MTT Cell Proliferation and Viability Assay Kit.  
To address the functional importance of HUVEC proliferation in response to growth factors, we 
incubated the cells for 48 hours in serum reduced medium (0.5% FCS) in the presence or 
absence of VEGF or EGF. Both growth factors at concentrations of 25 ng/ml induced endothelial 
cell proliferation under the starved conditions (Fig. 6.9). The results allow us to speculate that 
VEGF and EGF signalling pathways play a critical role in promoting endothelial cell survival 
under our in vitro conditions.  
Cell proliferation assays were performed to examine an in vitro inhibition of VEGF and EGF 
induced HUVEC growth following treatment with AZM475271. Inhibition of Src kinase in 
HUVECs by AZM475271 showed prevention of survival signaling from VEGF – and EGF – 
induced cell growth in a dose-dependent cytostasis. Interestingly, the IC50 concentration for 
AZM475271 in both VEGF- and EGF- stimulated HUVECs was significantly higher (Fig. 6.10) 
than that found under unstimulated conditions (Fig. 6.8a). The results allow us to speculate that 
VEGF and EGF signalling pathways play a critical role in promoting endothelial cell 
proliferation. 
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Figure 6.9 The effects of exogenous VEGF or EGF on endothelial cell 
proliferation. 
Both growth factors at concentrations of 25 ng/ml induced endothelial cell 
proliferation under the starved conditions. (* p<0.05 compared with 2% FCS 
control, # p<0.05 compared with 0.5% FCS starved control). 
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Figure 6.10 Inhibition of VEGF (A) – and EGF (B) – mediated endothelial cell 
proliferation. 
Cells were treated with AZM475271 (1 – 10 µmol/L) in the presence of human 
recombinant VEGF165 or human recombinant EGF at concentrations of 25 ng/ml 
in serum reduced Endothelial Cell Basal Medium. Inhibition of Src kinase in 
HUVECs by AZM475271 showed prevention of survival signaling from VEGF 
(A) – and EGF (B) – induced cell growth in a dose-dependent cytostasis. Box 
plots represent the means for each group with standard deviation of data (min and 
max) and standard error of the mean; *, p< 0.05 versus VEGF – stimulated cells; 
#, p< 0.05 versus EGF – stimulated cells. 
 
6.8 In vitro effect of AZM475271 in the aortic ring assay 
 
Angiogenesis was studied by culturing aortic explants in three-dimensional matrix gels 
according to the procedure of Nikosia and Ottineri. Endothelial cell sprouting from cultured rat 
aortic rings was abrogated by AZM475271 at any of the concentrations tested (1 µmol/l to 5 
µmol/L; Fig. 6.11). At a concentration of 1 µmol/L endothelial migration and sprouting was 52 
% relative to untreated controls (p = 0.0024 versus control). In contrast, a concentration of 5 
µmol/L inhibited sprouting by 93 % relative to controls (p < 0.0005 versus control; Fig. 6.7).  
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Figure 6.11 Effect of AZM475271 on rat aortic ring formation. 
An estimation of the length of the capillary was performed by measuring the 
distance from the aortic explant to the approximate mean point of capillary. 
Endothelial cell sprouting from cultured rat aortic rings was abrogated by 
AZM475271 (a) at any of the concentrations tested (1 µmol/L to 5 µmol/L). At a 
concentration of 1 µmol/L endothelial migration and sprouting was 52 % relative 
to untreated controls. By contrast, a concentration of 5 µmol/L inhibited sprouting 
by 93 % relative to controls (#, p<0.0004 versus AZM475271 0 µmol/L; *, p = 
0.0024 versus AZM475271 0 µmol/L). Representative photographs (b) showing 
the in vitro anti-angiogenic activity of the Src kinase inhibitor (the rings were 
examined by phase contrast microscopy with a Zeiss Axiotech Vario microscope 
at ×10 magnification, bar = 10 µm, the arrows delineate capillary outgrowth).  
 
   AZM 1 µM    AZM 3 µM 
   AZM 5 µM    Control 
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6.9 AZM475271 inhibits endothelial sprouting in vitro in the spheroid angiogenesis 
model 
 
To investigate the complex processes of angiogenesis in vitro, we used the spheroid assay. We 
measured the ability of the endothelial cells to form sprouts in the spheroid model as a result of 
angiogenic stimulation, a prerequisite for an engagement of these cells in the formation of blood 
vessels.  
Interestingly, AZM475271 inhibited sprouting of HUVEC at lower concentrations than 
suggested by the MTT proliferation assay (1 µmol/L for the sprouting assay versus 6 µmol/L for 
the MTT assay). At concentrations higher than the IC50, sprouting of the endothelial cell 
spheroids was completely prevented (Fig. 6.12).  
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Figure 6.12 AZM475271 inhibits endothelial sprouting in vitro in the spheroid angiogenesis 
model 
Spheroids were stimulated with 25 ng/ml VEGF-A165 and the inhibiting properties 
of AZM475271 were investigated. AZM475271 was able to overcome the 
stimulating effect of VEGF-A165 at micromolar concentrations. Representative 
Unstimulated VEGF 25 ng/ml 
AZM 1 µmol/L 
AZM 10 µmol/L AZM 5 µmol/L 
AZM 0.1 µmol/L 
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pictures of spheroids are presented (the pictures of the spheroids were taken under 
trans-illumination using an Achroplan objective providing a 20-fold 
magnification; the arrows delineate spheroid sprouting). 
 
6.10 Inhibition of VEGF production by L3.6pl and HUVE cells following treatment with 
AZM475271 
 
The level of VEGF was measured in cell culture supernates collected on day 0, 2, and 4 from 
L3.6pl or HUVE cells at one passage during treatment with Src kinase inhibitor AZM475271 at 
different concentrations (0.1 and 1 µmol/L). The assay was performed according to the 
manufacturer’s recommendations. Absorbance at 450 nm was measured and corrected using the 
540-nm reading on the microplate reader. VEGF content was calculated according to the 
parameter of the calibration curve. Calibration curves with a correlation coefficient at least 0.998 
were used and data are expressed as picograms per millilitre per 106 cells. All experiments were 
replicated three times. 
The concentrations of AZM475271 below or equal 1 µmol/L (the concentrations with a 
maximum of inhibitory effect against Src tyrosine kinase [Fig. 6.1] without antiproliferative 
activity on tumor or endothelial cells [Fig. 6.8]) were taken to show that the production of VEGF 
by tumor or endothelial cells is “Src-dependent”. We found that the level of VEGF in HUVE cell 
supernate on Day 0 (the beginning of experiment) as well as the level of VEGF in Endothelial 
Cell Basal Medium completed with supplemented growth factors was mostly non-detectable. 
The level of VEGF in HUVE cell supernate increased on Day 4, although this difference did not 
reach a significant level (Fig. 6.13a).  
The level of VEGF in supernate taken from L3.6pl cells was significantly higher (> 50-fold) 
compare to those found in the HUVE cell supernate on Day 2. The amount of VEGF expressing 
by L3.6pl cells on Day 4 after the beginning of experiment increased significantly (Fig. 6.13b).  
Most interestingly, the blockade of Src kinase by AZM475271 dramatically reduced the level of 
VEGF in L3.6pl supernate, the effect which was found also in the cell culture supernate from 
HUVE cells (Fig. 6.13, a and b). The inhibition of VEGF production by L3.6pl and HUVE cells 
following treatment with AZM475271 was day- and dose- dependent. 
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Figure 6.13 VEGF production by HUVE (a) and L3.6pl (b) cells following 
treatment with AZM475271. 
The level of VEGF was measured in cell culture supernates collected on day 0, 2, 
and 4 from L3.6pl or HUVECs at one passage. The blockade of Src kinase by 
AZM475271 significantly reduced the level of VEGF in L3.6pl supernate in a 
dose-dependent manner (b), the effect which was found also in the cell culture 
supernate from HUVECs (a). (*, p<0.05 versus AZM475271 0 µmol/L, Day 2; #, 
p<0.05 versus AZM475271 0 µmol/L, Day 4).    
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6.11 In vitro induction of cell death in HUVECs 
 
FACS analysis was used to determine the effects of AZM475271 on HUVEC cell cycle 
progression. Quantification of apoptosis was performed using propidium iodide staining. HUVECs 
were treated with AZM475271 in different concentrations for 12 hours, and then cells were collected 
and suspended in a Nicoletti buffer. Inhibition of Src kinase in HUVECs resulted in the induction of 
apoptosis in 99% of the cells treated with AZM475271 at concentrations from 10 up to 25 µM as 
compared with 6.3% of apoptotic cells present in the untreated control (Fig. 6.14, b). Interestingly, at 
the more physiologically relevant submicromolar doses of AZM475271 (5, 1 and 0.1 µmol/L) the 
level of apoptotic fraction was also significantly higher (60%, 40% and 15%, respectively) when 
compared with untreated cells (6%; Fig. 6.14, a). 
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Figure 6.14 In vitro effect of AZM475271 on endothelial cell survival. 
Quantification of apoptosis was performed using propidium iodide staining for 
cell cycle analysis by FACS. AZM475271 promotes HUVEC apoptosis in a dose-
dependent manner (a), (*, p<0.05 versus AZM475271 0 µmol/L). Histograms (b) 
show one representative of three independent experiments. 
 
 
6.12 In vitro inhibition of migration of HUVECs by AZM475271 
 
To investigate the anti-migratory effects of AZM475271 on endothelial cells we demonstrated 
whether Src inhibition in HUVECs prevented cell migration in a modified Boyden chamber 
assay. Inhibition of Src kinase resulted in a dose depended decrease of HUVEC migration. (p < 
0.05; Fig. 6.15). 
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Figure 6.15 In vitro inhibition of migration of HUVECs by AZM475271. 
Migration of HUVECs was demonstrated using a modified Boyden chamber 
assay. Inhibition of VEGF-induced chemotaxis was assessed after including 
AZM475271 at relevant doses. Migration through the membrane was determined 
after 4 hours of incubation at 37oC by fixing, staining with hematoxylin and eosin, 
and counting the migrated cells in five random fields at ×100 magnification. The 
average of triplicate inserts from three representative experiments was obtained. 
Bars, SD; *, p< 0.001; #, p< 0.0004 (both versus VEGF stimulation); §, positive 
cells in 5 random 0.159-mm2 fields at x100 magnification. 
 
 
6.13 AZM475271 abolishes VEGF-induced FAK phosphorylation in HUVECs 
 
Src tyrosine kinase has been shown to mediate the tyrosine phosphorylation signal from VEGFR 
to FAK. Focal adhesion kinase is involved in integrin-mediated signal transduction. It plays an 
important role in the control of several biological processes, including cell spreading, migration 
and survival (Parsons et al., 2000). The recruitment of Src family kinases results in the 
phosphorylation of tyrosine residues 576 and 577 in the catalytic domain. Phosphorylation of 
tyrosines 576 and 577 is significantly elevated in the presence of c-Src in vitro and v-Src in vivo 
(Calalb et al., 1995). Furthermore, the maximal kinase activity of FAK immune complexes 
requires phosphorylation of both tyrosines 576 and 577.  
  Chapter 6. Results  
 - 91 - 
Here, we test the possibility that AZM475271 could affect VEGF-induced FAK kinase activity 
in HUVECs. Using Western Blots, we found src-dependent up-regulation of FAK 
phosphorylation (Fig. 6.16). Treatment of HUVECs with 10 µmol/L of AZM475271 resulted in 
the significant inhibition of VEGF-activated pTyr 576/577 FAK phosphorylation, indicating that 
VEGF mediates its effect in HUVECs at least in part via Src kinase.  
 
     
 
 
Figure 6.16 VEGF-induced HUVEC FAK phosphorylation is inhibited by 
AZM475271. 
 Lysates of VEGF-stimulated HUVECs were prepared as described in Materials 
and Methods and subjected to immunoblotting with anti-phosphotyrosine antibody 
specific for 576/577 within FAK.  
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Chapter 7 
 
DISCUSSION 
               
 
 
Currently, a large variety of chemotherapeutic drugs is being used to treat pancreatic cancer, but, 
unfortunately, many compounds show only limited efficacy due to problems of delivery and 
development of drug resistance in tumor cells. Tumor cells are rapidly changing targets because 
of their genetic instability, heterogeneity, and high rate of mutation, leading to selection and 
outgrowth of drug-resistant tumor cell populations (Gasparini et al., 1999; Kerbel, 1997). 
Anti-angiogenic therapy offers several advantages over therapy directed against tumor cells. 
First, endothelial cells are a genetically more stable, diploid, and spontaneous mutations rarely 
occur. Second, the turnover of tumor endothelial cells is approximately 50 times higher than of 
endothelial cells in normal quiescent tissues. Third, tumor endothelial cells as target are easily 
accessible by systemic administration. Finally, a high number of tumor cells is sustained by a 
single capillary, that means, inhibition of a small number of tumor vessels may affect the growth 
of many tumor cells (Kerbel, 1997). It has been shown, that the intratumoral blood vessel density 
is a prognostic marker in a variety of solid tumors, including invasive breast (Kumar et al., 
1999), lung (Fontanini et al., 1996), malignant melanoma, gastrointestinal, (Tanigawa et al., 
1997) and genitourinary cancers (Pepper, 1997). The progressive growth of pancreatic 
neoplasms also depends on the induction of angiogenesis, in these tumors a positive correlation 
was found between tumor angiogenesis and the risk of metastasis, tumor recurrence, and death 
(Kumar et al., 1999; Fontanini et al., 1996; Tanigawa et al., 1997). However, as tumors grow, 
they begin to produce a wider array of angiogenic molecules. Therefore, if only one molecule 
(for example, VEGF) is blocked, tumors may switch to another molecule (for example, bFGF or 
IL-8). Thus we may require a cocktail of antibodies/inhibitors. In this respect, targeting 
intracellular proteins might be a promising approach in angiogenesis therapy of pancreatic 
cancer. Indeed, our results support the theory that the inhibition of intracellular transducers of 
receptor tyrosine kinase signaling can avoid these disadvantages.  
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The purpose of the current study was to determine whether the intracellular tyrosine kinase Src 
might play a role in angiogenesis of pancreatic cancer. c-Src is a multifunctional protein 
involved in the regulation of a variety of normal processes, including proliferation, 
differentiation, survival, motility, and functions of fully differentiated cells (Thomas and Brugge, 
1997). There are several recent reports that Src contributes to the control of tumor angiogenesis. 
Specifically, Src is needed for hypoxia-induced vascular endothelial growth factor (VEGF) 
production in a number of cell types (Mukhadopathyay et al., 1995). Furthermore, it has been 
shown, that suppression of Src in HT29 colon cancer cells by an antisense approach, led to a 
reduction of VEGF expression (Ellis et al., 1998). Thus, it appears that Src cannot only regulate 
the production of VEGF, but also control the consecutive endothelial cell response (see Chapter 
3). 
To investigate the hypothesis, that Src inhibitory drugs do not only affect tumor cell proliferation 
and survival, but also angiogenesis and migration, we conducted an in vivo experiment using a 
novel orally available Src kinase inhibitor AZM475271 (AstraZeneca) in nude mice bearing 
L3.6pl human pancreatic cancer implanted orthotopically in the pancreas. Treatment with 
AZM475271 did not significantly change animal weight (at the end of experiment the mean 
animal body weight after therapy with AZM475271 was 21.6 g, compared to the untreated group 
with 22.6 g). Monitoring of the tumor volume over the time of experiment revealed a decrease in 
the tumor growth progression in all animals treated with AZM475271. The animals were 
sacrificed 32 days after the initiation of treatment, when > 50% of the control animals had 
become moribund. At the time of sacrifice, all animals developed primary pancreatic tumors, 
however the mean tumor volume was significantly decreased (~40% inhibition of primary tumor 
growth) from 1125 ± 460 mm3 (control animals) to 508 ± 205 mm3 in animals treated with 
AZM475271. Furthemore, treatment with AZM475271 significantly reduced spontaneous liver 
metastasis (no animals had metastases) compared with treatment using vehicle solution. Mice 
who received AZM475271 had also a significant reduction in the incidence of lymph node 
metastases (five of nine animals). In addition, daily intragastral administration of AZM475271 
was well tolerated. IHC analyses of primary pancreatic tumors demonstrated a significant 
decrease in proliferating tumor cells, the mean number of Ki-67 positive tumor cells after 
therapy with AZM475271 was reduced by > 50 % compared to control mice. The mean number 
of apoptotic cells in the tumors treated with AZM475271 was significantly elevated compared to 
control tumors (26 ± 11 versus 8 ± 2, respectively). The number of CD31-positive microvessels 
counted per x100 field in the pancreatic tumors was lower in mice after therapy with 
AZM475271, but not significant (p = 0.14967). We speculated that tumor cell apoptosis may 
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have been due to poor perfusion after endothelial cell apoptosis rather then due to decreasing in 
microvessel density. Indeed, double staining of endothelial cells with antibodies against CD31 
and TUNEL revealed that the reduction in MVD was attributable to a significant increase of 
apoptosis in endothelial cells (24 ± 9.1 for AZM475271 compared with 0.7 ± 1.5 for untreated 
control, p = 0.01) and not to a direct effect on the tumor cells themselves (clusters of apoptotic 
tumor cells were seen surrounding apoptotic endothelial cells when treated with AZM475271). 
This finding suggests that the reduced tumor size that followed therapy with Src inhibitor was 
not wholly a direct consequence of inhibition of tumor cell proliferation. There was a statistically 
significant induction of endothelial cell apoptosis in the pancreatic tumor model when 
AZM475271-treated tumors and control tumors were compared. This is the first report to our 
knowledge demonstrating that therapy with AZM475271 leads to apoptosis of endothelial cells 
within pancreatic tumors as determined by a double-labeling immunofluorescence procedure. 
Moreover, the antiangiogenic activity of the Src kinase inhibitor was also evident in vitro, where 
proliferation, invasion, and migration of the endothelial cells were significantly reduced by 
AZM475271.  
In vitro, AZM475271 was shown to inhibit proliferation and to induce apoptosis of human 
umbilical vein endothelial cells (HUVECs) in a dose dependent manner. Treatment of HUVECs 
with AZM475271 at high concentrations (> 10 µmol/L) caused a rapid decrease in cell 
proliferation that could be linked to the ability of AZM475271 to induce HUVEC death, whereas 
a significant antiproliferative activity of AZM475271 on HUVECs could be already observed at 
concentrations of 2 µmol/L or above (IC50 = 6 µmol/L). Interestingly, no significant inhibition of 
proliferation was seen on L3.6pl cells at doses up to 5 µmol/L. The antiproliferative effect of 
AZM475271 on L3.6pl was seen exclusively at very high doses (IC50 = 25 µmol/L). These in 
vitro findings support our theory that the anti-tumor properties of AZM475271 might 
predominantly be mediated through a direct effect on the endothelial cells rather that on the 
tumor cells. 
Inhibition of Src kinase in HUVECs also showed prevention of survival signaling from VEGF 
and EGF. The IC50 concentration for AZM475271 in both VEGF- and EGF- stimulated 
HUVECs was higher (IC50 = 10 µmol/L) than that found in HUVECs under unstimulated 
conditions. The results allow us to speculate that VEGF and EGF signalling pathways play a 
critical role in promoting endothelial cell proliferation and survival. Indeed, it has been shown 
that receptor tyrosine kinases activate Src by autophosphorylation of tyrosine residues that 
function as docking sites for the SH2 domain of Src kinase on the receptor itself or by 
phosphorylation of docking proteins. Once activated, Src could link VEGF- or EGF-stimulation 
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with the PDK/PKB signaling cassette leading to stimulation of endothelial cell survival and 
angiogenesis (Schlessinger et al., 2000). However, although both growth factors stimulate Src 
activation, it has only been shown that VEGF-induced angiogenesis can be inhibited by 
treatment with a retrovirus that encodes for Src-251, a dominant-negative mutant of Src. 
Moreover, overexpression of Src-251 in avian blood vessels induces apoptotic death, indicating 
that VEGF-induced activation of Src is essential for endothelial cell survival and angiogenesis. 
Interestingly, VEGF-induced vascular permeability is impaired in Src-/- and in Yes-/- but not in 
Fyn-/- mice (Eliceiri et al., 1999), suggesting that the function of Src kinases in endothelial cells 
is not comparable to the function of other family members.  
Furthemore, we found that in addition to regulating the VEGF response of HUVE cells, Src also 
regulates the expression of VEGF in both tumor and endothelial cells. The level of VEGF was 
measured in cell culture supernates collected on day 0, 2, and 4 from L3.6pl or HUVE cells at 
one passage during treatment with Src kinase inhibitor AZM475271 at different concentrations 
(0.1 and 1 µmol/L). The concentrations of AZM475271 below or equal 1 µmol/L (the 
concentrations with a maximum of inhibitory effect against Src tyrosine kinase without 
antiproliferative activity on tumor or endothelial cells) were taken to show that the production of 
VEGF by tumor or endothelial cells is “Src-dependent”. We found that the level of VEGF in 
HUVE cell supernate on Day 0 (the beginning of experiment) as well as the level of VEGF in 
Endothelial Cell Basal Medium completed with supplemented growth factors was mostly non-
detectable. The level of VEGF in HUVE cell supernate increased on Day 4, although this 
difference did not reach a significant level. The level of VEGF in supernate taken from L3.6pl 
cells was significantly higher (> 50-fold) compare to those found in the HUVE cell supernate on 
Day 2. The amount of VEGF expressing by L3.6pl cells on Day 4 after the beginning of 
experiment increased significantly. Most interestingly, the blockade of Src kinase by 
AZM475271 dramatically reduced the level of VEGF in L3.6pl supernate, the effect which was 
found also in the cell culture supernate from HUVE cells.  
To gain more relevant information in terms of angiogenic processes, we measured the ability of 
the endothelial cells to form sprouts in the spheroid assay as a result of angiogenic stimulation, a 
prerequisite for an engagement of these cells in the formation of blood vessels. Cells organized 
in a spheroid that is embedded in a collagen matrix, are much more sensitive to pro-angiogenic 
as well as anti-angiogenic stimuli as compared to the same cells in a monolayer culture. This 
finding was also apparent in our experiments and is rationalized by the fact that proliferation is 
only one of the features of angiogenic processes. Additional processes such as cell plasticity and 
mobility are also pivotal features of angiogenesis. Therefore, our finding that AZM475271 
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abrogated the stimulating effect of VEGF-A165 even at submicromolar concentrations 
demonstrates the high susceptibility of sprouting endothelial cells to AZM475271.  
Image analysis was also used to quantify angiogenesis on the rat aortic ring model by culturing 
aortic explants in three-dimensional matrix gels according to the procedure of Nikosia and 
Ottineri. This model bridges the gap between in vivo and in vitro models and is suitable to 
quantify spontaneous angiogenesis as well as to analyze a complex microvascular network 
induced by VEGF. Interestingly, endothelial cell sprouting from cultured rat aortic rings was 
abrogated by AZM475271 at any of the concentrations tested (1 µmol/l to 5 µmol/L). At a 
concentration of 1 µmol/L endothelial migration and sprouting was 52 % relative to untreated 
controls. In contrast, a concentration of 5 µmol/L inhibited sprouting by 93 % relative to 
controls. 
Recent reports have demonstrated a major role for Src activity in the control of cell adhesion and 
cytoskeletal changes, which in turn regulate cell invasion and migration (Frame, 2002). To 
produce new vessels, endothelial cells must migrate, degrade extracellular matrix, divide, form 
tubes, and survive (Fidler et al., 1994; Folkman, 1995). Evidence is provided that VEGF 
activates Src kinase, which induces the phosphorylation of tyrosines 576/577 within FAK, 
facilitating the association of FAK with integrin αvβ3. Blockade of Src activity by AZM475271 
inhibits the formation of a VEGF-induced FAK/ αvβ3 complex. Integrin αvβ3 is known to bind a 
number of ECM proteins, among them vitronectin, fibrinogen, von Willebrand factor, 
fibronectin and denatured collagen. More recent studies show that integrin αvβ3 can also bind 
directly to matrix metalloproteinase 2, thereby localizing the MMP-2-mediated matrix-
degradation capacity to the invasive/migratory site of vascular cells during angiogenesis (Brooks 
et al., 1996). This enables endothelial cells to degrade and remodel the ECM during their 
invasion.  
We confirmed the antimigratory effect of AZM475271 by analysis of endothelial cell migration 
using a modified Boyden chamber assay revealing a strong inhibition of HUVEC migration. 
These findings suggest that one major role of Src activity is to cooperate with activated growth 
factor receptors to induce adhesion and cytoskeletal changes that are associated with invasion 
and metastasis. Therefore, it is possible, that Src-specific inhibitory drugs, such as AZM475271, 
might primarily affect these pathways in endothelial cells, and so be useful in preventing further 
tumor spread, while not necessarily having such a strong influence on cancer cell growth.  
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Chapter 8 
 
SUMMARY 
               
 
The results of all experiments can be summarized as follows: 
 
• AZM475271 is the selective inhibitor of the Src tyrosine kinase activity in HUVE and 
L3.6pl cells with the IC50 = 0.1 µmol/L; 
• Monitoring of the tumor volume in mice bearing human pancreatic cancer revealed a 
decrease in the tumor growth progression in all animals treated with AZM475271; 
• Daily intragastral administration of AZM475271 was well tolerated; 
• At the time of necropsy, the mean tumor volume was significantly decreased (~40% 
inhibition of primary tumor growth) in all mice treated with AZM475271; 
• Treatment with AZM475271 significantly reduced spontaneous liver metastasis (no 
animals had metastases) compared with treatment using vehicle solution. Mice who 
received AZM475271 had also a significant reduction in the incidence of lymph node 
metastases (five of nine animals); 
• The mean number of proliferating tumor cells (Ki-67-positive) in harvested tumors was 
reduced over than 50 % in the AZM475271 therapy group compared to the control group; 
• The mean number of apoptotic cells (measured by TUNEL staining) was significantly 
higher in the AZM475271 therapy group; 
• The number of endothelial cells undergoing apoptosis (determined by a double CD31 and 
TUNEL staining) was significantly greater in pancreatic tumors from mice treated with 
AZM475271 compared to control tumors; 
• A significant antiproliferative activity of AZM475271 on HUVECs can be already 
observed at concentrations of 2 µmol/L or above (IC50 = 6 µmol/L); 
• Treatment of HUVECs with AZM475271 at high concentrations (> 10 µmol/L) caused a 
rapid decrease in cell proliferation that could be linked to the ability of AZM475271 to 
induce HUVEC death (measured by MTT proliferation assay); 
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• Inhibition of Src kinase in HUVECs by AZM475271 showed prevention of survival 
signaling from VEGF – and EGF – induced cell growth in a dose-dependent manner 
(measured by MTT proliferation assay); 
• Endothelial cell sprouting from cultured rat aortic rings was abrogated by AZM475271 at 
any of the concentrations tested (1 µmol/l to 5 µmol/L); 
• AZM475271 inhibited sprouting of HUVEC in the spheroid angiogenesis model at lower 
concentrations than suggested by the MTT proliferation assay (1 µmol/L for the spheroid 
assay versus 6 µmol/L for the MTT assay).  
• The blockade of Src kinase by AZM475271 dramatically reduced the level of VEGF in 
L3.6pl and HUVEC supernates; 
• Src inhibition in HUVECs prevented VEGF – induced cell migration in the modified 
Boyden chamber assay; 
• Treatment of HUVECs with AZM475271 resulted in the significant inhibition of VEGF-
activated pTyr 576/577 FAK phosphorylation. 
 
Taken together, our results suggest that the Src kinase inhibitor AZM475271, in addition to its 
antiproliferative effects on pancreatic tumor cells, suppresses tumor growth in vivo potentially by 
anti-angiogenic mechanisms by inducing intratumoral endothelial cell apoptosis and finally 
reducing the MVD. It is an exciting prospect that Src inhibitory drugs might not only affect more 
traditional Src activities, such as cell growth, migration, and invasion, but could also induce 
endothelial cell death in regions of pancreatic tumors where neovascularisation is occurring. 
These findings are consistent with our in vitro studies, where AZM475271 was shown to 
significantly inhibit VEGF-induced endothelial cell proliferation, migration, spreading, and 
survival. VEGF production by L3.6pl cells was also inhibited following treatment with 
AZM475271, so angiogenesis inhibition found in vivo may be mediated, at least in part, by 
paracrine effects. 
Since AZM475271 is well tolerated when given to animals, we believe that the findings of the 
present study may shed light on the pharmacological basis for the clinical application of Src 
kinase inhibitors for suppression of angiogenesis, which plays a crucial role in pancreatic tumor 
growth and metastasis. 
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Chapter 9 
 
ZUSAMMENFASSUNG 
               
 
Die Ergebnisse der Doktorarbeit können wie folgt zusammengefasst werden: 
 
• AZM475271 ist ein selektiver inhibitor der Scr Tyrosinkinase-Aktivität in humanen 
vasklären Endothelzellen undin humanen Pankreaskarzinomzellen L3.6pl mit einem IC50 
= 0,1µmol/l 
• Durch regelmäßiges Monitring konnte im Tierexperiment eine Abnahme des 
Pankreastumorwachstums nach Behandlung mit AZM475271 festgestellt werden 
• Die tägliche intragastrale Verabreichung von AZM475271 wurde von allen Tieren gut 
vertragen 
• Zum Zeitpunkt der Tötung war das Tumorvolumen nach Behnadlung mit AZM475271 
signifikant niedriger (~ 40% niedriger) 
• Die Behandlung mit AZM475271 führte zu einer signifikanten Reduktion der Inzidenz 
von Leber- und Lymphknotenmetastasen   
• Die Anzahl der proliferierenden Zellen (Ki67 positiv) in den Pankreastumoren war nach 
Behandlung mit AZM475271 bis zu 50% im Vergelich zu den Kontrolltieren reduziert 
• Die mittlere Anzahl apoptotischer Zellen (TUNEL-Färbung) in den Pankreastumoren war 
signifikant höher nach Therapie mit AZM475271 als in den Kontrolltumoren 
• Die mitlere Anzahl apoptotischer Endothelzellen (TUNEL/CD31-Doppelfärbung) in den 
Pankreastumoren war signifikant höher nach Therapie mit AZM475271 als in 
Kontrolltumoren 
• In HUVECs zeigt sich bereits ab einer Konzentration von 2µmol/l (IC50 = 6µmol/l) ein 
signifikant anti-prolferativer Effekt im MTT-Assay 
• Die Behandlung von HUVECs mit hohen Dosen von AZM475271 (>10µmol/l) führt 
zum Zelltod  
• Die Blockade der Src Kinase in HUVECs durch AZM475271 zeigte eine dosis-
abhängige Inhibition des VEGF- und EGF induzierten Zellwachstums 
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• Das endotheliale „Sprouting“ kultivierter Rattenaortenringe konnte mit AZM475271 in 
Dosieurungen von 1-5µmol/l unterbunden werden. 
• AZM475271 führte zur Hemmung des „Sproutings“ im Spheroid-Angiogenese-Assay 
• Die Blockade der Src Kinase mit AZM475271 führte zur deutlichen Reduktion der 
VEGF-Konzentrationen in Überständen von kultivierten L3.6pl und HUVE-Zellen 
• Src Inhibition in HUVECs verhindert VEGF-induzierte Zellmigration in eine 
modifizieren Boyden Chamber Assay 
• Die Behandlung von HUVECs mit AZM475271 resultierte in einer signifikanten 
Inhibition der VEGF-aktivierten pTyr576/577 FAK-Phosphorylierung 
 
Schlußfolgernd lassen diese Ergebnisse vermuten, daß die Reduktion des 
Pankreastumorwachstums durch den Src Kinase inhibitor AZM475271 zum einen durch den 
anti-proliferativen Effekt auf die Pankreastumorzellen bedingt ist, desweiteren allerdings durch 
einen potentiell anti-angiogenetischen Mechanismus durch Induktion der intratumoralen 
Apoptose von Endothelzellen und damit Reduktion der Mikrogefäßdichte im Tumor. Das 
Spektrum Src-inhibierender Substanzen beschränkt sich daher nicht nur auf ihre anti-
migratorische, anti-invasive oder anti-proliferative Wirkunsgweisen, sondern kann auch auf anti-
angiogenetische Effekte erweitert werden.  
Die in vivo Ergebnisse im orthotopen Pankreastumor-Mausmodell sind in den in vitro 
Experimenten nachvollziehbar: der Src Kinase Inhibitor AZM475271 führte zur signifikanten 
Reduktion des VEGF-induzierten Überlebens, der Proliferation, Migration und des „Sproutings“. 
Die tumorzelleigene VEGF-Produktion konnte durch den Src Kinase Inhibitor AZM475271 
deutlich reduziert werden, so daß anzunehmen ist, daß die Angiogenese-Inhibition auch zum 
Teil  durch parakrine Effekte vermittelt wird.  
Da AZM475271 im Tierexperiment gut verträglich war, ist vorstellbar, daß Src Kinase 
Inhibitoren nach Kenntnis ihrer pharmakologischen Effektivität – auch als anti-angiogenetische 
Substanz – eine klinische Applikation insbesondere beim metastasierten Pankreaskarzinom 
finden könnten. 
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ABBREVIATIONS 
               
 
5-FU 5-Fluorouracil 
Ang1 Angiopoietin 1 
APS Ammonium-persulfate 
ATP Adenosine triphosphate 
AUR-3 Aurora kinase  
BCA Bicinchoninic acid  
bFGF Basic fibroblast growth factor 
BSA Bovine serum albumine 
CDK-2 Cyclin-dependent kinase-2  
cDNA Complementary deoxyribonucleic acid 
Chk Csk-homologous kinase 
CSF1-R Colony stimulation factor-1 receptor 
Csk C-terminal Src kinase 
DAPI 4',6-diamino-2-phenylindole  
dFdCDP Gemcitabine-diphosphate  
dFdCTP Gemcitabine-triphosphate  
DMEM Dulbecco's modified Eagles medium 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic acid 
dTMP Deoxythymidine-5'-monophosphate 
DTT D,1-Dithiothreitol  
dUMP Deoxyuridine-5'-monophosphate 
ECL Enhanced chemiluminescence 
ECM Extracellular matrix 
EDTA Ethylenediamine-tetra acetic acid 
EGF Epidermal growth factor  
ERK Extracellular regulated kinase 
FACS Fluorescence-activated cell sorting 
FAK Focal adhesion kinase 
FBS Fetal bovine serum  
FCS Fetal calf serum 
FGF Fibroblast growth factor  
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Flt-1 fms-like tyrosine kinase 1  
Flt3 Fms like tyrosine kinase-3 
GDP Guanosine 5'-Diphosphate 
GTP Guanosine 5'-Triphosphate 
H&E Haematoxylin and eosin 
HGF Hepatocyte growth factor 
HRP Horseradish peroxidase 
HUVEC Human umbilical vein endothelial cells  
Ig Immunoglobulin 
IGF Insulin growth factor 
IL Interleukin 
JAK Janus kinase 
JM Juxtamembrane 
KDR Kinase insert domain-containing receptor  
Lck Lymphocyte-specific protein tyrosine kinase 
LN Lymph node 
Lyn Lck/Yes related novel tyrosine kinase 
MAPK Mitogen-activated protein kinase 
MEK Mitogen-activated protein kinase kinase 
MMP Matrix metalloproteinase  
mRNA Messenger ribonucleic acid 
MVD Microvessel density 
NF-κB Nuclear factor-κB 
PAGE Polyacrylamid gel electrophoresis 
PDGF Plateled-derived growth factor 
PI Propidium iodide  
PI3-K Phosphatidylinositol 3-kinase 
PKB Protein kinase B 
PKC Protein kinase C 
PML Promyelocytic leukemia 
PMSF Phenylmethylsulfonyl fluoride  
PP2 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine 
PTK Protein tyrosine kinase  
PTP Protein tyrosine phosphatase 
RNA Ribonucleic acid 
RTK Receptor tyrosine kinase 
SDS Sodium dodecyl sulfate 
SFK Src family kinase 
SH Src homology 
Src Raus sarcoma virus proto-oncogene product 
STAT Signal transducers and activators of transcription 
TEMED N,N,N',N'-Tetra-methylethylenediamine 
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TGF-β transforming growth factor-β 
TKD Tyrosine kinase domain 
TMB 3,3′,5,5′-Tetramethylbenzidine 
TNF-α tumor necrosis factor-α 
TS Thymidylate synthase  
TUNEL Terminal deoxynucleotidyl transferase-mediated nick end labeling  
VEGF Vascular endothelial growth factor 
Yes Yamaguchi 73 and Esh avian sarcoma 
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Professional skills 
 
Basic cell culture techniques 
In vitro and in vivo development of drug-resistant cell lines 
Detection of viable cells 
BrdU incorporation assay 
Invasion and chemotaxis methods 
Cell cycle analyses  
Determination of apoptotic cells by FACS analysis 
Enzyme-linked immunoassays  
Immunoprecipitation analysis 
Western blot analysis 
In vitro kinase assays 
Proteomics 
Plasmid DNA isolation 
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Total RNA extraction and RT-PCR 
Aortic ring assay  
Spheroid angiogenesis assay 
In vitro wound-healing assay 
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